



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/475, C12N 5/10, 15/62, C07K 16/26, A61K 38/18, A01K 67/027	A1	(11) International Publication Number: WO 99/41377 (43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/US99/03104 (22) International Filing Date: 12 February 1999 (12.02.99) (30) Priority Data: 09/023,570 13 February 1998 (13.02.98) US (71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US). (72) Inventors: SHEPPARD, Paul, O.; 20717 N.E. 2nd Street, Redmond, WA 98053 (US). LOK, Si; 806 N.W. 52nd Street, Seattle, WA 98107 (US). (74) Agent: PARKER, Gary; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>	
(54) Title: NOVEL CYSTINE KNOT PROTEIN AND MATERIALS AND METHODS FOR MAKING IT (57) Abstract The present invention relates to polynucleotide and polypeptide molecules for zsig51, a novel member of the cystine knot family of polypeptides. The polypeptides comprise a sequence of amino acid residues that is at least 80 % identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2. The invention further provides therapeutic and diagnostic methods utilizing the polynucleotides, polypeptides, and antagonists of the polypeptides.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	R	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

5

NOVEL CYSTINE KNOT PROTEIN AND
MATERIALS AND METHODS FOR MAKING IT

BACKGROUND OF THE INVENTION

10 In multicellular animals, cell growth, differentiation, and migration are controlled by polypeptide growth factors and hormones. These growth factors play a role in both normal development and pathogenesis, including the development of solid tumors.

15 Polypeptide growth factors and hormones influence cellular events by binding to cell-surface receptors. Binding initiates a chain of signalling events within the cell, which ultimately results in phenotypic changes such as cell division and production of additional hormones.

20 One family of hormones is the glycoprotein hormone family, which includes luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, and chorionic gonadotropin. The first three are synthesized in the anterior pituitary, while chorionic gonadotropin is synthesized in the placenta, reaching a maximum at 10-12 weeks after conception and declining thereafter to the end of pregnancy.

25 The four glycoprotein hormones are structurally and functionally related. All four are glycosylated and consist of two non-covalently associated subunits, term α and β subunits. A single α subunit is common to all four hormones, while the β subunits are unique and confer biological specificity. The different β subunits are of similar size and have a significant degree of pairwise homology; the β subunits of human chorionic gonadotropin (HCG) and human luteinizing hormone are 82% identical, and the other pairs of β subunits are about 30-40% identical. Twelve cysteine residues are conserved among
30 the four β subunits. The common α subunit exhibits detectable homology to the β subunits and includes six of the twelve conserved cysteine residues. See, Fiddes and Goodman, *Nature* 281:351-356, 1979; Fiddes and Goodman, *Nature* 286:684-687, 1980; Talmadge et al., *Nature* 307:37-40, 1984; and
35 Pi rce and Parsons, *Ann. Rev. Biochem.* 50:465-495, 1981. The polypeptides form characteristic higher-order structures having a bow tie-like configuration

about a cystine knot, formed by disulfide bonding between three pairs of cysteine residues. Dimerization occurs through hydrophobic interactions between loops of the two monomers. See, Daopin et al., *Science* 257:369, 1992; Laphorn et al., *Nature* 369:455, 1994.

5 The cystine knot motif and bow tie-like fold are also characteristic of the growth factors transforming growth factor-beta (TGF- β), nerve growth factor (NGF), and platelet derived growth factor (PDGF). These proteins are all dimers in their active forms, the monomer subunits of which contain from 100 to 130 amino acid residues. Although their amino acid sequences are quite
10 divergent, these proteins, as well as the glycoprotein hormones, all contain the six conserved cysteine residues of the cystine knot.

 The glycoprotein hormones act in a stage- and tissue-specific manner. LH, FSH, and TSH are produced in the pituitary. Luteinizing hormone stimulates steroid production in the testes and ovaries, which in turn stimulates
15 spermatogenesis and ovulation. FSH is also a regulator of gametogenesis and steroid hormone synthesis in the gonads. TSH regulates a variety of processes in the thyroid, thereby controlling synthesis and secretion of thyroid hormones. HCG, produced in placenta, stimulates the ovaries to produce steroids that are necessary for the maintenance of pregnancy. For review see Pierce and
20 Parsons, *Ann. Rev. Biochem.* 50:465-495, 1981.

 A more recently discovered member of this family, designated Norrie disease protein (NDP), is believed to be a regulator of neural cell differentiation and proliferation (Berger et al., *Nature Genetics* 1:199-203, 1992). NDP is expressed in retina, choroid, and fetal and adult brain. A lack of
25 functional NDP is associated with Norrie disease, an X-linked disorder characterized by blindness, deafness, and mental disturbances. A number of variant forms of the protein, including deletions and point mutations, have been identified in Norrie disease patients. See, for example, Berger et al., *ibid.*; Fuchs et al., *Hum. Mol. Genet.* 3:655-656, 1994; and Meindl et al., *Nature*
30 *Genetics* 2:139-143, 1992.

 Another group of related proteins is the growth and differentiation factors (GDFs). One member of this group, known as GDF-8 or myostatin, appears to act as a negative regulator of muscle mass (McPherron and Lee, *Nature* 387:83-90, 1997; McPherron and Lee, *Proc. Natl. Acad. Sci. USA*
35 94:12457-12461, 1997; and Grobet et al., *Nat. Genet.* 17:17-71, 1997). Many GDFs share 20-40% sequence homology with each other and with TGF- β 1, 2,

and 3. The discovery of the GDFs supports the postulated existence of "chalones", soluble factors hypothesized to control organ size and regeneration (Bullough, *Cancer Res.* 25:1683-1727, 1965; Bullough, *Biol. Res.* 37:307-342, 1992).

5 The role of hormones in controlling cellular processes makes them likely candidates and targets for therapeutic intervention. Examples of such proteins that are used therapeutically include insulin for the treatment of diabetes and erythropoietin for the treatment of anemia. Gonadotropin has been used to induce ovulation (e.g., Fleming, *Am. J. Obstet. Gynecol.* 159:376-381, 1988), to induce scrotal descent of cryptorchid testes (Lala et al., *J. Urol.* 157:1898-1901, 1997), and to stimulate intratesticular testosterone production in men who have undergone varicocele (Yamamoto et al., *Arch. Androl.* 35:49-55, 1995). Clinical studies have shown that hCG can have antitumor activity against Kaposi's sarcoma (Gill et al., *J. Natl. Cancer Inst.* 89:1797-1802, 1997). Assays for the presence of chorionic gonadotropin are used to detect pregnancy. Vaccines against hCG have shown promising results in early tests for preventing pregnancy and inhibiting the growth of hormone-dependent cancers (Talwar, *Immunol. Cell Biol.* 75:184-189, 1997).

20 In view of the proven clinical utility of hormones, there is a need in the art for additional such molecules for use as therapeutic agents, diagnostic agents, and research tools and reagents.

 The present invention provides such polypeptides for these and other uses that should be apparent to those skilled in the art from the teachings herein.

25

SUMMARY OF THE INVENTION

 Within one aspect of the invention there is provided an isolated polypeptide that is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2. The polypeptide comprises cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2, a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2, and beta strands corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2. Within one embodiment of the invention the isolated polypeptide further comprises cysteine residues at positions corresponding to residues 25, 65, 80, and 101 of SEQ ID NO:2. Within a further embodiment, amino acid residues within the polypeptide at positions

corresponding to residues 8, 11, 12, 14, 29, 30, 32, 34, 43, 44, 60, 63, 64, 65, 71, 74, 80, 90, 91, 93, and 94 of SEQ ID NO:2 are Cys, His, Pro, Asn, His, Val, Gln, Cys, Phe, Pro, Thr, Ser, Gln, Cys, Leu, Val, Cys, Ile, Phe, Ala, and Arg, respectively, and an amino acid residue corresponding to residue 75 of SEQ ID NO:2 is Lys or Arg. Within other embodiments the isolated polypeptide comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29. Within further embodiments, the isolated polypeptide is covalently linked to an affinity tag or to an immunoglobulin constant region.

Within a second aspect of the invention there is provided an isolated protein comprising a first polypeptide complexed to a second polypeptide wherein said protein modulates cell proliferation, differentiation, or metabolism. The first polypeptide is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2 and comprises cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2, a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2, and beta strands corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2. Within one embodiment the first polypeptide further comprises cysteine residues at positions corresponding to residues 25, 65, 80, and 101 of SEQ ID NO:2. Within a further embodiment, amino acid residues of the first polypeptide corresponding to residues 8, 11, 12, 14, 29, 30, 32, 34, 43, 44, 60, 63, 64, 65, 71, 74, 80, 90, 91, 93, and 94 of SEQ ID NO:2 are Cys, His, Pro, Asn, His, Val, Gln, Cys, Phe, Pro, Thr, Ser, Gln, Cys, Leu, Val, Cys, Ile, Phe, Ala, and Arg, respectively; and an amino acid residue corresponding to residue 75 of SEQ ID NO:2 is Lys or Arg. Within another embodiment the protein is a heterodimer. Within a related embodiment the second polypeptide is a glycoprotein hormone common alpha subunit. Within other embodiments the first polypeptide comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29. Within further embodiments, the protein is a homodimer, such as a homodimer of polypeptides comprising residue 1 through residue 106 of SEQ ID NO:2, or a homodimer of polypeptides comprising residue 1 through residue 106 of SEQ ID NO:29.

Within a third aspect of the invention there is provided an isolated polynucleotide encoding a polypeptide that is at least 90% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2, wherein the

polypeptide comprises cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2, a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2, and beta strands corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2.

5 Within one embodiment the polypeptide further comprises cysteine residues at positions corresponding to residues 25, 65, 80, and 101 of SEQ ID NO:2. Within another embodiment, amino acid residues of the polypeptide corresponding to residues 8, 11, 12, 14, 29, 30, 32, 34, 43, 44, 60, 63, 64, 65, 71, 74, 80, 90, 91, 93, and 94 of SEQ ID NO:2 are Cys, His, Pro, Asn, His, Val, 10 Gln, Cys, Phe, Pro, Thr, Ser, Gln, Cys, Leu, Val, Cys, Ile, Phe, Ala, and Arg, respectively, and an amino acid residue corresponding to residue 75 of SEQ ID NO:2 is Lys or Arg. Within certain additional embodiments of the invention, the polypeptide comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29. Within another embodiment 15 the polynucleotide further encodes a secretory peptide operably linked to the polypeptide. Within additional embodiments the polynucleotide encodes residue -23 through residue 106 of SEQ ID NO:2 or residue -23 through residue 106 of SEQ ID NO:29. Within further embodiments the polynucleotide comprises a sequence of nucleotides as shown in SEQ ID NO:4 or SEQ ID 20 NO:30 from nucleotide 70 through nucleotide 387. Within other embodiments, the polynucleotide comprises a sequence of nucleotides as shown in SEQ ID NO:1 from nucleotide 125 through nucleotide 442. Within an additional embodiment the polynucleotide is from 318 to 1000 nucleotides in length. The polynucleotide can be DNA or RNA.

25 Within a fourth aspect of the invention there is provided an expression vector comprising the following operably linked elements: (a) a transcription promoter; (b) a DNA segment encoding a polypeptide as disclosed above; and (c) a transcription terminator. Within one embodiment the DNA segment further encodes a secretory peptide operably linked to the 30 polypeptide. Within further embodiments the DNA segment encodes residue -23 through residue 106 of SEQ ID NO:2 or residue -23 through residue 106 of SEQ ID NO:29.

35 Within a fifth aspect of the invention there is provided a cultured cell into which has been introduced an expression vector as disclosed above, wherein the cell expresses the polypeptide encoded by the DNA segment. The cell can be used within a method of producing a polypeptide, wherein the

method comprises culturing the cell, whereby the cell expresses the polypeptide encoded by the DNA segment, and recovering the expressed polypeptide.

5 Within a further aspect of the invention there is provided an antibody that specifically binds to an epitope of a polypeptide as disclosed above.

10 The invention also provides a method for detecting a genetic abnormality in a patient, comprising the steps of (a) obtaining a genetic sample from a patient; (b) incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product; (c) comparing the first reaction product to a control reaction product, wherein a difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the patient.

15 The invention also provides an oligonucleotide probe or primer comprising 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:4 or a sequence complementary to SEQ ID NO:4. Within one embodiment the probe or primer comprises 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:1 or a sequence complementary to SEQ ID NO:1.

20 The invention also provides a pharmaceutical composition comprising a polypeptide as disclosed above in combination with a pharmaceutically acceptable vehicle.

25 These and other aspects of the invention will become evident upon reference to the following detailed description of the invention and the attached drawings.

BRIEF DESCRIPTION OF THE DRAWING

30 The figure is a Hopp/Woods hydrophilicity profile of the amino acid sequence shown in SEQ ID NO:2. The profile is based on a sliding six-residue window. Buried G, S, and T residues and exposed H, Y, and W residues were ignored. These residues are indicated in the figure by lower case letters.

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

The term "affinity tag" is used herein to denote a polypeptide
5 segment that can be attached to a second polypeptide to provide for
purification of the second polypeptide or provide sites for attachment of the
second polypeptide to a substrate. In principal, any peptide or protein for which
an antibody or other specific binding agent is available can be used as an
affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al.,
10 *EMBO J.* 4:1075, 1985; Nilsson et al., *Methods Enzymol.* 198:3, 1991),
glutathione S transferase (Smith and Johnson, *Gene* 67:31, 1988), Glu-Glu
affinity tag (Grussenmeyer et al., *Proc. Natl. Acad. Sci. USA* 82:7952-7954,
1985), substance P, Flag™ peptide (Hopp et al., *Biotechnology* 6:1204-1210,
1988), maltose binding protein (Kellerman and Ferenci, *Methods Enzymol.*
15 90:459-463, 1982; Guan et al., *Gene* 67:21-30, 1987), streptavidin binding
peptide, thioredoxin, ubiquitin, cellulose binding protein, T7 polymerase,
immunoglobulin constant domain, or other antigenic epitope or binding domain.
See, in general, Ford et al., *Protein Expression and Purification* 2: 95-107,
1991. DNAs encoding affinity tags and otehr reagents are available from
20 commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ; Eastman
Kodak, New Haven, CT; New England Biolabs, Beverly, MA).

The term "allelic variant" is used herein to denote any of two or
more alternative forms of a gene occupying the same chromosomal locus.
Allelic variation arises naturally through mutation, and may result in phenotypic
25 polymorphism within populations. Gene mutations can be silent (no change in
the encoded polypeptide) or may encode polypeptides having altered amino
acid sequence. The term allelic variant is also used herein to denote a protein
encoded by an allelic variant of a gene.

The terms "amino-terminal" and "carboxyl-terminal" are used
30 herein to denote positions within polypeptides. Where the context allows, these
terms are used with reference to a particular sequence or portion of a
polypeptide to denote proximity or relative position. For example, a certain
sequence positioned carboxyl-terminal to a reference sequence within a
polypeptide is located proximal to the carboxyl terminus of the reference
35 sequence, but is not necessarily at the carboxyl terminus of the complete
polypeptide.

A "beta-strand-like region" is a region of a protein characterized by certain combinations of the polypeptide backbone dihedral angles phi (ϕ) and psi (ψ). Regions wherein ϕ is less than -60° and ψ is greater than 90° are beta-strand-like. Those skilled in the art will recognize that the limits of a β -strand are somewhat imprecise and may vary with the criteria used to define them. See, for example, Richardson and Richardson in Fasman, ed., Prediction of Protein Structure and the Principles of Protein Conformation, Plenum Press, New York, 1989; and Lesk, Protein Architecture: A Practical Approach, Oxford University Press, New York, 1991.

A "complement" of a polynucleotide molecule is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

A plurality of polypeptide chains are "complexed with" each other when they are associated, covalently (e.g., by disulfide bonding) or non-covalently (e.g., by hydrogen bonding, hydrophobic interactions, or salt-bridge interactions), to form a protein having a characteristic biological activity.

"Corresponding to", when used in reference to a nucleotide or amino acid sequence, indicates the position in a second sequence that aligns with the reference position when two sequences are optimally aligned.

The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.

Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions
5 such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 316:774-78, 1985).

An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from
10 blood and animal tissue. In a preferred form, the isolated polypeptide or protein is substantially free of other polypeptides or proteins, particularly other polypeptides or proteins of animal origin. It is preferred to provide the polypeptides or proteins in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term
15 "isolated" does not exclude the presence of the same polypeptide or protein in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended
20 purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result
25 of speciation.

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and
30 synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be
35 equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly

in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

5 A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

 The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the
10 binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

 A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic
15 substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

20 A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

25 Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

30 All references cited herein are incorporated by reference in their entirety.

 The present invention is based in part upon the discovery of a novel DNA molecule that encodes a polypeptide having a secretory peptide and an arrangement of cysteine residues and beta strand-like regions that is
35 characteristic of the gonadotropin family of glycoprotein hormones. The DNA molecule was originally identified in a library of cDNAs derived from pancreatic

strand 3 → variable loop 2 → beta strand 4 → cystine knot → beta strand 5 → variable loop 3 → beta strand 6 → cystine knot. Variable loop 1 is disulfid bonded to variable loop 2 to form one side of the bow tie, with variable loop 3 forming the other side.

5 Structural analysis and homology indicate that zsig51 polypeptides complex with a second polypeptide to form multimeric proteins. These proteins include homodimers and heterodimers. In the latter case, the second polypeptide can be a truncated or other variant zsig51 polypeptide or another polypeptide, such as a glycoprotein hormone subunit, TGF-β
10 polypeptide, a GDF polypeptide, or a bone morphogenic protein (BMP) polypeptide. Among the dimeric proteins within the present invention are dimers formed by non-covalent association (e.g., hydrophobic interactions) with a second subunit, either a second zsig51 polypeptide or other second subunit, such as a common α subunit. Within these dimers, loops 1 and 3 of monomer
15 1 interact with loop 2 of monomer 2, and loop 2 of monomer 1 interacts with loops 1 and 3 of monomer 2. In addition, dimerization may occur via intermolecular disulfide bond formation. Alignment with TGF-β indicates that Cys-65 may participate in an intermolecular disulfide bond.

20 The present invention also provides isolated polypeptides that are substantially homologous to the polypeptides of SEQ ID NO:2 and their orthologs. Such polypeptides will preferably be at least 95% or more identical to residues 1-106 of SEQ ID NO:2 or its orthologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., *Bull. Math. Bio.* 48:603-616, 1986, and Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to
25 optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 1 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

30

Total number of identical matches

x 100

35

[length of the longer sequence plus the
number of gaps introduced into the longer
sequence in order to align the two
sequences]

The level of identity between amino acid sequences can be determined using the "FASTA" similarity search algorithm of Pearson and Lipman (*Proc. Natl. Acad. Sci. USA* 85:2444, 1988), and by Pearson (*Meth. Enzymol.* 183:63, 1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO:2) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, *J. Mol. Biol.* 48:444, 1970; Sellers, *SIAM J. Appl. Math.* 26:787, 1974), which allows for amino acid insertions and deletions. Illustrative parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, 1990 (*ibid.*).

FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from four to six.

The present invention includes polypeptides having one or more conservative amino acid changes as compared with the amino acid sequence of SEQ ID NO:2. The BLOSUM62 matrix (Table 1) is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, *ibid.*). Thus, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid

sequences of the present invention. As used herein, the term "conservative amino acid substitution" refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. Preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least one 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).

Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions and other changes that do not significantly affect the folding or activity of the protein or polypeptide, and include amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an extension that facilitates purification (an affinity tag) as disclosed above. Proteins having such an extension will preferably comprise a region that is at least 95% identical to residues 1 through 106 of SEQ ID NO:2, or an ortholog thereof.

The present invention further provides a variety of other polypeptide fusions and related multimeric proteins comprising one or more polypeptide fusions. For example, a zsig51 polypeptide can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region domains. Immunoglobulin-zsig51 polypeptide fusions can be expressed in genetically engineered cells to produce a variety of multimeric zsig51 analogs. Auxiliary domains can be fused to zsig51 polypeptides to target them to specific cells, tissues, or macromolecules (e.g., collagen). For example, a zsig51 polypeptide or protein can be targeted to a predetermined cell type by fusing a zsig51 polypeptide to a ligand that specifically binds to a receptor on the surface of the target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A zsig51 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., *Connective Tissue Research* 34:1-9, 1996.

The polypeptides of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs, an *E. coli* S30 extract, and commercially available enzymes and other reagents. See, for example, Robertson et al., *J. Am. Chem. Soc.* 113:2722, 1991; Ellman et al., *Methods Enzymol.* 202:301, 1991; Chung et al., *Science* 259:806-809, 1993; and Chung et al., *Proc. Natl. Acad. Sci. USA* 90:10145-10149, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., *J. Biol. Chem.* 271:19991-19998, 1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). See, Koide et al., *Biochem.* 33:7470-7476, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, *Protein Sci.* 2:395-403, 1993).

Amino acid sequence changes are made in zsig51 polypeptides so as to minimize disruption of higher order structure essential to biological activity. Changes in amino acid residues will be made so as not to disrupt the cystine knot and "bow tie" arrangement of loops that is characteristic of the protein family. The effects of amino acid sequence changes can be predicted by computer modeling as disclosed above or determined by analysis of crystal structure (see, e.g., Lapthorn et al., *ibid.*). A hydrophobicity profile of SEQ ID NO:2 is shown in the attached figure. Those skilled in the art will recognize that this hydrophobicity will be taken into account when designing alterations in the amino acid sequence of a zsig51

polypeptide, so as not to disrupt the overall profile. Alignment of zsig51 with other family members also provides guidance in selecting amino acid substitutions, particularly if information about the effects of amino acid substitutions in other family members is available. For example, alignment suggests that residue 95 (Ala) can be replaced with Ser. This variant sequence is shown in SEQ ID NO:29. Alignment with NDP, taking into account reported deleterious mutations, indicates that residues 8, 11, 12, 14, 29, 30, 32, 34, 43, 44, 60, 63, 64, 65, 71, 74, 75, 80, 90, 91, 93, and 94 may be relatively intolerant of substitution or deletion. Residue 75 (Lys in SEQ ID NO:2) may be conservatively replaced with Arg. The region of zsig51 from the penultimate Cys residue to the carboxyl terminus (residues 98 to 106 of SEQ ID NO:2) may be important for receptor specificity.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244, 1081-1085, 1989; Bass et al., *Proc. Natl. Acad. Sci. USA* 88:4498-4502, 1991). Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (*Science* 241:53-57, 1988) or Bowie and Sauer (*Proc. Natl. Acad. Sci. USA* 86:2152-2156, 1989). Other methods that can be used include phage display (e.g., Lowman et al., *Biochem.* 30:10832-10837, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., *Gene* 46:145, 1986; Ner et al., *DNA* 7:127, 1988).

Variants of the disclosed zsig51 DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389-391, 1994 and Stemmer, *Proc. Natl. Acad. Sci. USA* 91:10747-10751, 1994. Briefly, variant genes are generated by *in vitro* homologous recombination by random fragmentation of a parent gene followed by reassembly using PCR, resulting in randomly introduced point mutations.

Mutagenesis methods as disclosed above can be combined with high volume or high-throughput screening methods to detect biological activity of zsig51 variant polypeptides, in particular biological activity in modulating cell proliferation or cell differentiation. For example, mitogenesis assays that measure dye incorporation or ³H-thymidine incorporation can be carried out on large numbers of samples, as can cell-based assays that

detect expression of a reporter gene (e.g., a luciferase gene). These and other assays are disclosed in more detail below. Mutagenized DNA molecules that encode active zsig51 polypeptides can be recovered from the host cells and rapidly sequenced using modern equipment. These methods
5 allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

Using the methods discussed above, one of ordinary skill in the art can identify and/or prepare a variety of polypeptides that are substantially
10 homologous to residues 1 through 106 of SEQ ID NO: 2 or allelic variants or orthologs thereof and retain the biological properties of the wild-type protein. Such polypeptides can also include additional polypeptide segments as generally disclosed above.

The present invention also provides polynucleotide molecules,
15 including DNA and RNA molecules, that encode the zsig51 polypeptides disclosed above. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO:4 is a degenerate DNA sequence that encompasses all DNAs that encode the
20 zsig51 polypeptide of SEQ ID NO: 2. Those skilled in the art will recognize that the degenerate sequence of SEQ ID NO:4 also provides all RNA sequences encoding SEQ ID NO:2 by substituting U for T. Thus, zsig51 polypeptide-encoding polynucleotides comprising nucleotide 70 to nucleotide 387 of SEQ ID NO: 4 and their RNA equivalents are contemplated by the
25 present invention. A degenerate sequence encoding SEQ ID NO:29 is shown in SEQ ID NO:30. Table 2 sets forth the one-letter codes used within SEQ ID NO:4 and SEQ ID NO:30 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the
30 code Y denotes either C or T, and its complement R denotes A or G, A being complementary to T, and G being complementary to C.

TABLE 3

Amino Acid	One-Letter Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	CAN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
Asn Asp	B		RAY
Glu Gln	Z		SAR
Any	X		NNN
Gap	-	---	

One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by

the degenerate sequences may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:29. Variant sequences can be readily tested for functionality as described herein.

5 For any zsig51 polypeptide, including variants and fusion proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 2 and 3 above. Moreover, those of skill in the art can use standard software to devise zsig51 variants based upon the
10 nucleotide and amino acid sequences described herein. The present invention thus provides a computer-readable medium encoded with a data structure that provides at least one of the following sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:38, and SEQ ID NO:39. Suitable
15 forms of computer-readable media include magnetic media and optically-readable media. Examples of magnetic media include a hard or fixed drive, a random access memory (RAM) chip, a floppy disk, digital linear tape (DLT), a disk cache, and a ZIP disk. Optically readable media are exemplified by compact discs (e.g., CD-read only memory (ROM), CD-rewritable (RW), and
20 CD-recordable), and digital versatile/video discs (DVD) (e.g., DVD-ROM, DVD-RAM, and DVD+RW).

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:1, or a sequence complementary thereto, under stringent conditions. In general,
25 stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is up to
30 about 0.03 M at pH 7 and the temperature is at least about 60°C.

As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. Complementary DNA (cDNA) clones are prepared from RNA that is isolated from a tissue or cell that produces large amounts of
35 zsig51 RNA. Such tissues and cells are identified by Northern blotting (Thomas, *Proc. Natl. Acad. Sci. USA* 77:5201, 1980), and include pancreas, pituitary, testis, and eye. Total RNA can be prepared using guanidine HCl

extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., *Biochemistry* 18:52-94, 1979). Poly (A)⁺ RNA is prepared from total RNA using the method of Aviv and Leder (*Proc. Natl. Acad. Sci. USA* 69:1408-1412, 1972). Complementary DNA (cDNA) is prepared from poly(A)⁺ RNA using known methods. In the alternative, genomic DNA can be isolated. For some applications (e.g., expression in transgenic animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron. Methods for identifying and isolating cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequence disclosed herein, or parts thereof, for probing or priming a library. Polynucleotides encoding zsig51 polypeptides are identified and isolated by, for example, hybridization or polymerase chain reaction ("PCR", Mullis, U.S. Patent 4,683,202). Expression libraries can be probed with antibodies to zsig51, receptor fragments, or other specific binding partners.

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOS:1 and 2 represent a single allele of human zsig51. Allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures.

The present invention further provides counterpart polynucleotides and polypeptides from other species (orthologs). Of particular interest are zsig51 polynucleotides and polypeptides from other mammalian species, including murine, rat, porcine, ovine, bovine, canine, feline, equine and other primate proteins. Orthologs of the human polynucleotides can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A zsig51-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned by PCR using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA

zsig51 residues 63-68

degenerate: WSN CAR TGY TGY ACN AT (SEQ ID NO:17)

consensus: WSN CAN TGY TGY MSN MY (SEQ ID NO:18)

5 complement: WSN GTN ACR ACR KSN KR (SEQ ID NO:19)

zsig51 residues 11-16

degenerate: CAY CCN TTY AAY GTN AC (SEQ ID NO:20)

consensus: MRN CMN YWY WAY GTN RM (SEQ ID NO:21)

10 complement: KYN GKN RWR WTR CAN YK (SEQ ID NO:22)

Zsig51 polynucleotide sequences disclosed herein can also be used as probes or primers to clone 5' non-coding regions of a zsig51 gene.

15 In view of the tissue-specific expression observed for zsig51 by Northern blotting, this gene region is expected to provide for pancreas-, testis-, eye-, and pituitary-specific expression. Promoter elements from a zsig51 gene could thus be used to direct the tissue-specific expression of heterologous genes in, for example, transgenic animals or patients treated with gene

20 therapy. Cloning of 5' flanking sequences also facilitates production of zsig51 proteins by "gene activation" as disclosed in U.S. Patent No. 5,641,670. Briefly, expression of an endogenous zsig51 gene in a cell is altered by introducing into the zsig51 locus a DNA construct comprising at least a targeting sequence, a regulatory sequence, an exon, and an unpaired

25 splice donor site. The targeting sequence is a zsig51 5' non-coding sequence that permits homologous recombination of the construct with the endogenous zsig51 locus, whereby the sequences within the construct become operably linked with the endogenous zsig51 coding sequence. In this way, an endogenous zsig51 promoter can be replaced or supplemented

30 with other regulatory sequences to provide enhanced, tissue-specific, or otherwise regulated expression.

The polynucleotides of the present invention can also be prepared by automated synthesis. Synthesis of polynucleotides is within the level of ordinary skill in the art, and suitable equipment and reagents are

35 available from commercial suppliers. See, in general, Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA,

interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Expression of zsig51 polypeptides via a host cell secretory pathway is expected to result in the production of multimeric proteins. As noted above, such multimers include both homomultimers and heteromultimers, the latter including proteins comprising only zsig51 polypeptides and proteins including zsig51 and heterologous polypeptides. For example, a heteromultimer comprising a zsig51 polypeptide and a common alpha subunit can be produced by co-expression of the two polypeptides in a host cell. A cDNA sequence encoding a common alpha subunit is disclosed by Fiddes and Goodman, *Nature* 281:351-356, 1979. A cDNA encoding the beta subunit of human chorionic gonadotropin is disclosed by Fiddes and Goodman, *Nature* 286:684-687, 1980. Berger et al., *Nature Genetics* 1:199-203, 1992 disclose cDNA clones encoding Norrie disease protein. A TGF- β cDNA is disclosed by Derynck et al., *Nature* 316:701-705, 1985. If a mixture of proteins results from expression, individual species are isolated by conventional methods. Monomers, dimers, and higher order multimers are separated by, for example, size exclusion chromatography. Heteromultimers can be separated from homomultimers by immunoaffinity chromatography using antibodies specific for individual dimers or by sequential immunoaffinity steps using antibodies specific for individual component polypeptides. See, in general, U.S. Patent No. 5,094,941. Multimers may also be assembled *in vitro* upon incubation of component polypeptides under suitable conditions. Recovery and assembly of proteins expressed in bacterial cells is disclosed below.

Cultured mammalian cells are suitable hosts for use within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., *ibid.*), and liposome-mediated transfection (Hawley-Nelson et al., *Focus* 15:73, 1993; Ciccarone et al., *Focus* 15:80, 1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed by, for example, Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and

Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica* nuclear polyhedrosis virus (AcNPV). See, King and Possee, The Baculovirus Expression System: A Laboratory Guide, London, Chapman & Hall; O'Reilly et al., Baculovirus Expression Vectors: A Laboratory Manual, New York, Oxford University Press., 1994; and Richardson, Ed., Baculovirus Expression Protocols. Methods in Molecular Biology, Humana Press, Totowa, NJ, 1995. Recombinant baculovirus can also be produced through the use of a transposon-based system described by Luckow et al. (*J. Virol.* 67:4566-4579, 1993). This system, which utilizes transfer vectors, is commercially available in kit form (Bac-to-Bac™ kit; Life Technologies, Rockville, MD). The transfer vector (e.g., pFastBac1™; Life Technologies) contains a Tn7 transposon to move the DNA encoding the protein of interest into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins and Possee, *J. Gen. Virol.* 71:971-976, 1990; Bonning et al., *J. Gen. Virol.* 75:1551-1556, 1994; and Chazenbalk and Rapoport, *J. Biol. Chem.* 270:1543-1549, 1995. In addition, transfer vectors can include an in-frame fusion with DNA encoding a polypeptide extension or affinity tag as disclosed above. Using techniques known in the art, a transfer vector containing a zsig51-encoding sequence is transformed into *E. coli* host cells, and the cells are screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, such as Sf9 cells. Recombinant virus that expresses zsig51 protein is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.

For protein production, the recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, *Spodoptera frugiperda* (e.g., Sf9 or Sf21 cells) or *Trichoplusia ni* (e.g., High Five™ cells; Invitrogen, Carlsbad, CA). See, in general, Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994. See also, U.S. Patent No. 5,300,435. Serum-free media are used to grow and maintain the cells. Suitable media formulations are known in the art and can be obtained from commercial suppliers. The cells are grown up from an inoculation density of approximately $2-5 \times 10^5$ cells to a density of $1-2 \times 10^6$ cells, at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to

10, more typically near 3. Procedures used are generally described in available laboratory manuals (e.g., King and Possee, *ibid.*; O'Reilly et al., *ibid.*; Richardson, *ibid.*).

Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279. The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in U.S. Patents No. 5,716,808 and No. 5,736,383, and WIPO Publications WO 97/17450 and WO97/17451. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*).

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for

Rapp, *Chem. Pept. Prot.* 3:3, 1986; and Atherton et al., Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, 1989.

Using methods known in the art, zsig51 proteins can be prepared as monomers or multimers; glycosylated or non-glycosylated; 5 pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.

Activity of zsig51 polypeptides and proteins can be measured *in vitro* using cultured cells or *in vivo* by administering molecules of the claimed invention to the appropriate animal model. For example, mitogenic activity 10 can be measured using known assays, including ³H-thymidine incorporation assays (as disclosed by, e.g., Raines and Ross, *Methods Enzymol.* 109:749-773, 1985), dye incorporation assays (as disclosed by, for example, Mosman, *J. Immunol. Meth.* 65:55-63, 1983 and Raz et al., *Acta Trop.* 68:139-147, 1997) or cell counts. A preferred mitogenesis assay measures the 15 incorporation of the dye Alamar blue (Raz et al., *ibid.*) into pancreatic or hypothalamic cells. See also, Gospodarowicz et al., *J. Cell. Biol.* 70:395-405, 1976; Ewton and Florini, *Endocrinol.* 106:577-583, 1980; and Gospodarowicz et al., *Proc. Natl. Acad. Sci. USA* 86:7311-7315, 1989. Differentiation can be assayed using suitable precursor cells that contain a differentiation-specific 20 reporter element. For example, pancreatic precursor cells can be used to measure the ability of a zsig51 protein to stimulate differentiation into a specific pancreatic cell type (e.g., β -islet cells). An islet cell-specific promoter, such as an insulin gene promoter, can be linked to a reporter gene, such as a luciferase gene, whereby luciferase is expressed in the 25 differentiated islet cells but not in the precursors. Precursor cells containing the reporter element can be obtained, for example, from mice made transgenic for the reporter element. A similar strategy can be applied to assay the effect of zsig51 protein on hypothalamic precursor cells and other cell types.

30 Zsig51 polypeptides and proteins can be assayed *in vivo* through the use of viral delivery systems. Exemplary viruses for this purpose include adenovirus, herpesvirus, vaccinia virus and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid 35 (reviewed by Becker et al., *Meth. Cell Biol.* 43:161-89, 1994; and Douglas and Curiel, *Science & Medicine* 4:44-53, 1997). The adenovirus system offers several advantages: adenovirus can (i) accommodate relatively large

DNA inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with a large number of available vectors containing different promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection.

5 By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts can be incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene is deleted from the viral vector, and the virus does not
10 replicate unless the E1 gene is provided by the host cell (e.g., the human 293 cell line). When intravenously administered to intact animals, adenovirus primarily targets the liver. If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in the host cells. However, the host's tissue (e.g., liver) will express and process (and, if a signal sequence is
15 present, secrete) the heterologous protein. Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.

Mice engineered to express the zsig51 gene, referred to as "transgenic mice", and mice that exhibit a complete absence of zsig51 gene
20 function, referred to as "knockout mice", can also be generated (Snouwaert et al., *Science* 257:1083, 1992; Lowell et al., *Nature* 366:740-742, 1993; Capecchi, *Science* 244:1288-1292, 1989; Palmiter et al. *Annu. Rev. Genet.* 20:465-499, 1986). For example, transgenic mice that over-express zsig51, either ubiquitously or under a tissue-specific or tissue-restricted promoter,
25 can be used to determine if over-expression causes a phenotype. For example, over-expression of a wild-type zsig51 polypeptide, polypeptide fragment, or a mutant thereof may alter normal cellular processes, resulting in a phenotype that identifies a tissue in which zsig51 expression is functionally relevant and may indicate a therapeutic target for the zsig51, its
30 agonists or antagonists. Moreover, such over-expression may result in a phenotype that shows similarity with human diseases. Similarly, knockout zsig51 mice can be used to determine where zsig51 is absolutely required *in vivo*. The phenotype of knockout mice may be predictive of the *in vivo* effects of a zsig51 antagonist such as those described herein. The murine zsig51
35 cDNA can be used to isolate murine genomic DNA, which is subsequently used to generate knockout mice. These mice can be employed to study the zsig51 gene and the protein encoded thereby in an *in vivo* system, and can

If a mammal has an insufficiency of zsig51 polypeptide (due to, for example, a mutated or absent zsig51 gene), the zsig51 gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a zsig51 polypeptide is introduced *in vivo* in a viral vector. Such
5 vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral
10 vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kaplitt et al., *Molec. Cell. Neurosci.* 2:320-30, 1991); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. (*J. Clin. Invest.* 90:626-30, 1992); and a defective adeno-associated virus
15 vector (Samulski et al., *J. Virol.* 61:3096-101, 1987; Samulski et al., *J. Virol.* 63:3822-28, 1989).

Within another embodiment, the zsig51 gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No.
20 5,399,346; Mann et al., *Cell* 33:153, 1983; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., *J. Virol.* 62:1120, 1988; Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Kuo et al., *Blood* 82:845-852, 1993. In the alternative, the vector can be
25 introduced by lipofection *in vivo* using liposomes. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-17, 1987; Mackey et al., *Proc. Natl. Acad. Sci. USA* 85:8027-31, 1988). The use of lipofection to introduce exogenous genes into specific organs *in vivo* has
30 certain practical advantages, including the ability to direct transfection to particular cells. Directing transfection to particular cell types is particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, or brain. Lipids can be chemically coupled to other molecules for the purpose of targeting. Targeted peptides (e.g., hormones or
35 neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

Within another embodiment, target cells are removed from the body, heterologous DNA is introduced as a naked DNA plasmid, and the cells are re-implanted in the body. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g.,
5 transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e.g., Wu et al., *J. Biol. Chem.* 267:963-67, 1992; Wu et al., *J. Biol. Chem.* 263:14621-24, 1988.

The present invention further provides antisense
10 polynucleotides that are complementary to a segment of the polynucleotides set forth in SEQ ID NO: 1. Such synthetic antisense oligonucleotides are designed to bind to mRNA encoding zsig51 polypeptides and to inhibit translation of such mRNA. Such antisense oligonucleotides are used to inhibit expression of zsig51 polypeptide-encoding genes in cell culture or in a
15 subject. Antisense approaches may be applied in the treatment of conditions such as cancers or hyperplasias of the pancreas or pituitary, pituitary hormone hypersecretion, prolactin hypersecretion, growth hormone hypersecretion (acromegaly), and ACTH hypersecretion (Cushing's disease).

The present invention also provides reagents for use in
20 diagnostic applications. The human zsig51 gene has been localized to chromosome band 11q13. Several other genes of interest have been localized to this region of chromosome 11, including tumor suppressor gene *MEN1* (multiple endocrine neoplasia type 1, an autosomal dominant familial cancer syndrome characterized by tumors in enteropancreatic endocrine
25 tissues, anterior pituitary, and parathyroid, and by peptic ulcers), which has been positionally cloned (Chandrasekharappa et al., *Science* 276:404-407, 1997), and a second, as yet uncloned, gene also associated with *MEN1*-like symptoms (Chakrabarti et al., *Genes Chromosomes Cancer* 22:130-137, 1998). Zsig51 is a candidate for this as yet unidentified disease gene, as
30 well as for IDDM4, an insulin-dependent diabetes mellitus susceptibility locus on 11q13, and for Bardet-Biedl syndrome type 1. Thus, the zsig51 gene, a probe comprising zsig51 DNA or RNA, or a subsequence thereof can be used to determine if the zsig51 gene is present on chromosome 11 or if a mutation has occurred. Detectable chromosomal aberrations at the zsig51
35 gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. These aberrations can occur within the coding sequence, within introns, or

within flanking sequences, including upstream promoter and regulatory regions, and may be manifested as physical alterations within a coding sequence or changes in gene expression level. Analytical probes will generally be at least 20 nucleotides in length, although somewhat shorter probes (14-17 nucleotides) can be used. PCR primers are at least 5 nucleotides in length, preferably 15 or more nt, more preferably 20-30 nt. Short polynucleotides can be used when a small region of the gene is targeted for analysis. For gross analysis of genes, a polynucleotide probe may comprise an entire exon or more. Probes will generally comprise a polynucleotide linked to a signal-generating moiety such as a radionucleotide. In general, these diagnostic methods comprise the steps of (a) obtaining a genetic sample from a patient; (b) incubating the genetic sample with a polynucleotide probe or primer as disclosed above, under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product; and (c) comparing the first reaction product to a control reaction product. A difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the patient. Genetic samples for use within the present invention include genomic DNA, cDNA, and RNA. The polynucleotide probe or primer can be RNA or DNA, and will comprise a portion of SEQ ID NO:1, the complement of SEQ ID NO:1, or an RNA equivalent thereof. Suitable assay methods in this regard include molecular genetic techniques known to those in the art, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, ligation chain reaction (Barany, *PCR Methods and Applications* 1:5-16, 1991), ribonuclease protection assays, and other genetic linkage analysis techniques known in the art (Sambrook et al., *ibid.*; Ausubel et al., *ibid.*; A.J. Marian, *Chest* 108:255-65, 1995). Ribonuclease protection assays (see, e.g., Ausubel et al., *ibid.*, ch. 4) comprise the hybridization of an RNA probe to a patient RNA sample, after which the reaction product (RNA-RNA hybrid) is exposed to RNase. Hybridized regions of the RNA are protected from digestion. Within PCR assays, a patient genetic sample is incubated with a pair of oligonucleotide primers, and the region between the primers is amplified and recovered. Changes in size, amount, or sequence of recovered product are indicative of mutations in the patient. Another PCR-based technique that can be employed is single strand conformational polymorphism (SSCP) analysis (Hayashi, *PCR Methods and Applications* 1:34-38, 1991).

antibody can bind. See, for example, Geysen et al., *Proc. Natl. Acad. Sci. USA* 81:3998-4002, 1984. Epitopes can be linear or conformational, the latter being composed of discontinuous regions of the protein that form an epitope upon folding of the protein. Linear epitopes are generally at least 6 amino acid residues in length. Relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, Sutcliffe et al., *Science* 219:660-666, 1983. Antibodies that recognize short, linear epitopes are particularly useful in analytic and diagnostic applications that employ denatured protein, such as Western blotting (Tobin, *Proc. Natl. Acad. Sci. USA* 76:4350-4356, 1979). Antibodies to short peptides may also recognize proteins in native conformation and will thus be useful for monitoring protein expression and protein isolation, and in detecting zsig51 proteins in solution, such as by ELISA or in immunoprecipitation studies.

Antigenic, epitope-bearing polypeptides of the present invention are useful for raising antibodies, including monoclonal antibodies, that specifically bind to a zsig51 protein. Antigenic, epitope-bearing polypeptides contain a sequence of at least six, preferably at least nine, more preferably from 15 to about 30 contiguous amino acid residues of a zsig51 protein (e.g., SEQ ID NO:2). Polypeptides comprising a larger portion of a zsig51 protein, i.e. from 30 to 50 residues up to the entire sequence are included. It is preferred that the amino acid sequence of the epitope-bearing polypeptide is selected to provide substantial solubility in aqueous solvents, that is the sequence includes relatively hydrophilic residues, and hydrophobic residues are substantially avoided.

As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')₂ and Fab fragments, single chain antibodies, and the like, including genetically engineered antibodies. Non-human antibodies can be humanized by grafting only non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon

administration to humans is reduced. One skilled in the art can generate humanized antibodies with specific and different constant domains (i.e., different Ig subclasses) to facilitate or inhibit various immune functions associated with particular antibody constant domains.

5 Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to zsig51 polypeptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled zsig51 polypeptide). Human antibodies can be produced in transgenic, non-human animals that have
10 been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination.

 Antibodies are defined to be specifically binding if they bind to a
15 zsig51 polypeptide with an affinity at least 10-fold greater than the binding affinity to control (non-zsig51) polypeptide. It is preferred that the antibodies exhibit a binding affinity (K_a) of 10^6 M^{-1} or greater, preferably 10^7 M^{-1} or greater, more preferably 10^8 M^{-1} or greater, and most preferably 10^9 M^{-1} or greater. The affinity of a monoclonal antibody can be readily determined by
20 one of ordinary skill in the art (see, for example, Scatchard, *Ann. NY Acad. Sci.* 51: 660-672, 1949).

 Methods for preparing polyclonal and monoclonal antibodies are well known in the art (see for example, Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, Inc., Boca
25 Raton, FL, 1982). As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats. The immunogenicity of a zsig51 polypeptide may be increased through the use of an adjuvant such as alum (aluminum hydroxide) or
30 Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of a zsig51 polypeptide or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such
35 portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

A variety of assays known to those skilled in the art can be utilized to detect antibodies that specifically bind to zsig51 polypeptides. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988.

- 5 Representative examples of such assays include concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, Western blot assays, inhibition or competition assays, and sandwich assays.

- 10 Antibodies to zsig51 can be used, for example, to isolate zsig51 polypeptides by affinity purification; for diagnostic assays for determining circulating or localized levels of zsig51 polypeptides; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block zsig51 activity *in vitro* and *in vivo*.

- 15 Antibodies and polypeptides disclosed herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides, and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention may be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance).
- 20 More specifically, zsig51 polypeptides or anti-zsig51 antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule. Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and
- 25 include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles, and the like. Cytotoxic molecules can be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, saporin, abrin, and the like), as well as
- 30 therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies can also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable
- 35 or cytotoxic molecule may be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to

the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/anticomplementary pair.

In another embodiment, polypeptide-toxin fusion proteins or antibody-toxin or fragment-toxin fusion proteins may be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Target cells (i.e., those displaying the zsig51 receptor) bind the zsig51-toxin conjugate, which is then internalized, killing the cell. The effects of receptor-specific cell killing (target ablation) are revealed by changes in whole animal physiology or through histological examination. Thus, ligand-dependent, receptor-directed cytotoxicity can be used to enhance understanding of the physiological significance of a protein ligand. A preferred such toxin is saporin. Mammalian cells have no receptor for saporin, which is non-toxic when it remains extracellular. Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain-only fusion protein includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell- or tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

In another embodiment, polypeptide-cytokine fusion proteins or antibody-cytokine fusion proteins may be used for enhancing *in vitro* cytotoxicity (for instance, that mediated by monoclonal antibodies against tumor targets) and for enhancing *in vivo* killing of target tissues (for example, blood and bone marrow cancers). See, generally, Hornick et al., *Blood* 89:4437-4447, 1997). In general, cytokines are toxic if administered systemically. The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable zsig51 polypeptides or anti-zsig51 antibodies target an undesirable cell or tissue (e.g., a tumor), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include, for example, interleukin-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The bioactive polypeptide and antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

Inhibitors of zsig51 activity (zsig51 antagonists) include anti-
5 zsig51 antibodies and soluble zsig51 receptors, as well as other peptidic and non-peptidic agents (including ribozymes). Such antagonists can be used to block the effects of zsig51 *in vitro* and *in vivo*. Of particular interest is the use of antagonists of zsig51 activity in cancer therapy. As early detection
10 methods improve it becomes possible to intervene at earlier times in tumor development, making it feasible to use inhibitors of angiogenesis to block the angiogenic switch that precedes the progression to invasive cancer. Inhibitors of zsig51 activity can be used in combination with other cancer therapeutic agents.

For pharmaceutical use, the proteins of the present invention
15 are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a zsig51 protein in combination with a pharmaceutically acceptable vehicle, such as saline,
20 buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in *Remington: The Science and Practice of Pharmacy*, Gennaro, ed., Mack Publishing Co.,
25 Easton, PA, 19th ed., 1995. Therapeutic doses will generally be in the range of 0.1 to 100 $\mu\text{g/kg}$ of patient weight per day, preferably 0.5-20 $\mu\text{g/kg}$ per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Doses of zsig51 protein will generally be
30 administered on a daily to weekly schedule, with individual doses typically within the range of 0.1 - 10 mg/patient. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general,
35 a therapeutically effective amount of zsig51 is an amount sufficient to produce a clinically significant change in the targetted condition.

The invention is further illustrated by the following non-limiting examples.

Example 1: Production a Pancreatic Islet Cell cDNA Library

5 RNA extracted from pancreatic islet cells was reverse transcribed in the following manner. The first strand cDNA reaction contained 10 μ l of human pancreatic islet cell poly d(T)-selected poly (A)⁺ mRNA (Clontech Laboratories, Inc., Palo Alto, CA) at a concentration of 1.0 mg/ml, and 2 μ l of 20 pmole/ μ l first strand primer ZC6171 (SEQ ID NO:23) containing an *Xho* I restriction site. The mixture was heated at 70°C for 2.5 minutes and cooled by chilling on ice. First strand cDNA synthesis was initiated by the addition of 8 μ l of first strand buffer (5x SUPERScript™ buffer; Life Technologies, Gaithersburg, MD), 4 μ l of 100 mM dithiothreitol, and 3 μ l of a deoxynucleotide triphosphate (dNTP) solution containing 10 mM each of dTTP, dATP, dGTP and 5-methyl-dCTP (Pharmacia LKB Biotechnology, Piscataway, NJ) to the RNA-primer mixture. The reaction mixture was incubated at 40° C for 2 minutes, followed by the addition of 10 μ l of 200 U/ μ l RNase H⁻ reverse transcriptase (SUPERScript II®; Life Technologies). The efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 μ Ci of ³²P- α dCTP to a 5 μ l aliquot from one of the reaction mixtures to label the reaction for analysis. The reactions were incubated at 40°C for 5 minutes, 45°C for 50 minutes, then incubated at 50°C for 10 minutes. Unincorporated ³²P- α dCTP in the labeled reaction was removed by chromatography on a 400 pore size gel filtration column (Clontech Laboratories, Inc.). The unincorporated nucleotides and primers in the unlabeled first strand reactions were removed by chromatography on 400 pore size gel filtration column. The length of labeled first strand cDNA was determined by agarose gel electrophoresis.

30 The second strand reaction contained 102 μ l of the unlabeled first strand cDNA, 30 μ l of 5x polymerase I buffer (125 mM Tris-HCl, pH 7.5, 500 mM KCl, 25 mM MgCl₂, 50mM (NH₄)₂SO₄), 2.0 μ l of 100 mM dithiothreitol, 3.0 μ l of a solution containing 10 mM of each deoxynucleotide triphosphate, 7 μ l of 5 mM β -NAD, 2.0 μ l of 10 U/ μ l *E. coli* DNA ligase (New England Biolabs), 5 μ l of 10 U/ μ l *E. coli* DNA polymerase I (New England Biolabs, Beverly, MA), and 1.5 μ l of 2 U/ μ l RNase H (Life Technologies). A 10 μ l aliquot from one of the second strand synthesis reactions was labeled by the addition of 10 μ Ci ³²P- α dCTP to monitor the efficiency of second

strand synthesis. The reactions were incubated at 16° C for two hours, followed by the addition of 1 µl of a 10 mM dNTP solution and 6.0 µl T4 DNA polymerase (10 U/µl, Boehringer Mannheim, Indianapolis, IN) and incubated for an additional 10 minutes at 16°C. Unincorporated ³²P-αdCTP in the
5 reaction mixture was removed by chromatography through a 400 pore size gel filtration column before analysis by agarose gel electrophoresis. The reaction was terminated by the addition of 10.0 µl 0.5 M EDTA and extraction with phenol/chloroform and chloroform followed by ethanol precipitation in the presence of 3.0 M Na acetate and 2 µl of Pellet Paint carrier (Novagen,
10 Madison, WI). The yield of cDNA was estimated to be approximately 2 µg from starting mRNA template of 10 µg.

Eco RI adapters were ligated onto the 5' ends of the cDNA described above to enable cloning into an expression vector. A 12.5 µl aliquot of cDNA (~2.0 µg) and 3 µl of 69 pmole/µl of Eco RI adapter
15 (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) were mixed with 2.5 µl 10x ligase buffer (660 mM Tris-HCl pH 7.5, 100 mM MgCl₂), 2.5 µl of 10 mM ATP, 3.5 µl 0.1 M DTT and 1 µl of 15 U/µl T4 DNA ligase (Promega Corp., Madison, WI). The reaction was incubated 1 hour at 5°C, 2 hours at 7.5°C, 2 hours at 10°C, 2 hours at 12.5°C and 16 hours at 10° C. The reaction was
20 terminated by the addition of 65 µl H₂O and 10 µl 10X H buffer (Boehringer Mannheim, Indianapolis, IN) and incubation at 70°C for 20 minutes.

To facilitate the directional cloning of the cDNA into an expression vector, the cDNA was digested with *Xho* I, resulting in a cDNA having a 5' Eco RI cohesive end and a 3' *Xho* I cohesive end. The *Xho* I
25 restriction site at the 3' end of the cDNA had been previously introduced. Restriction enzyme digestion was carried out in a reaction mixture by the addition of 1.0 µl of 40 U/µl *Xho* I (Boehringer Mannheim). Digestion was carried out at 37°C for 45 minutes. The reaction was terminated by incubation at 70°C for 20 minutes and chromatography through a 400 pore
30 size gel filtration column.

The cDNA was ethanol precipitated, washed with 70% ethanol, air dried and resuspended in 10.0 µl water, 2 µl of 10X kinase buffer (660 mM Tris-HCl, pH 7.5, 100 mM MgCl₂), 0.5 µl 0.1 M DTT, 2 µl 10 mM ATP, 2 µl T4 polynucleotide kinase (10 U/µl, Life Technologies). Following incubation at
35 37°C for 30 minutes, the cDNA was ethanol precipitated in the presence of 2.5 M ammonium acetate, and electrophoresed on a 0.8% low melt agarose gel. The contaminating adapters and cDNA below 0.6 kb in length were

excised from the gel. The electrodes were reversed, and the cDNA was electrophoresed until concentrated near the lan origin. The area of the gel containing the concentrated cDNA was excised and placed in a microfuge tube, and the approximate volume of the gel slice was determined. An aliquot of water approximately three times the volume of the gel slice (300 μ l) and 35 μ l 10x β -agarose I buffer (New England Biolabs) were added to the tube, and the agarose was melted by heating to 65°C for 15 minutes. Following equilibration of the sample to 45°C, 3 μ l of 1 U/ μ l β -agarase I (New England Biolabs, Beverly, MA) was added, and the mixture was incubated for 60 minutes at 45°C to digest the agarose. After incubation, 40 μ l of 3 M Na acetate was added to the sample, and the mixture was incubated on ice for 15 minutes. The sample was centrifuged at 14,000 x g for 15 minutes at room temperature to remove undigested agarose. The cDNA was ethanol precipitated, washed in 70% ethanol, air-dried and resuspended in 40 μ l water.

Following recovery from low-melt agarose gel, the cDNA was cloned into the *Eco* RI and *Xho* I sites of a phagemid vector (pBluescript II SK⁺; Stratagene, La Jolla, CA) and electroporated into DH10B cells. Bacterial colonies containing ESTs of known genes were identified and eliminated from sequence analysis by reiterative cycles of probe hybridization to hi-density colony filter arrays (Genome Systems, St. Louis, MI). cDNAs of known genes were pooled in groups of 50 - 100 inserts and were labeled with ³²P- α CTP using a MEGAPRIME labeling kit (Amersham, Arlington Heights, IL). Colonies which did not hybridize to the probe mixture were selected for sequencing. Sequencing was done using automated equipment. The resulting data were analyzed, resulting in the identification of a novel EST designated SISF1000391. The sequence of this EST is shown in SEQ ID NO:24. The plasmid containing this insert was designated pSLSIG51-1. The insert was sequenced and found to comprise the sequence shown in SEQ ID NO:1.

Subsequent to the cloning of pSLSIG51-1, a zsig51 clone was identified in a pituitary cDNA library.

Example 2: Tissue Distribution of Zsig51

Blots of human RNA (Human Multiple Tissue Northern Blots I, II, and III; and Human RNA Master Blot; Clontech Laboratories, Inc., Palo Alto, CA) were probed to determine the tissue distribution of zsig51. A cDNA

probe was generated using 20 pmoles each of oligonucleotide primers ZC16,013 (SEQ ID NO:25) and ZC16,014 (SEQ ID NO:26) and 5 μ l of a pancreas cDNA library (prepared from pancreas RNA using a commercially available kit (Marathon™ cDNA Amplification Kit from Clontech Laboratories, Inc.) and diluted 1:100). The probe was generated by PCR, incubating the reaction mixture at 94°C for 1 minute followed by 30 cycles of 94°C, 20 seconds; 64°C, 30 seconds; 72°C, 30 seconds; then a final extension for 7 minutes at 72°C. Reaction products were electrophoresed on a 1.25% Tris-borate/EDTA gel, and the 180 bp product was excised from the gel. DNA was extracted from the gel slab using a commercially available kit (QIAquick™ Gel Extraction Kit; Qiagen, Inc., Santa Clarita, CA). This PCR product was sequenced and found to be a portion of the zsig51 sequence. 98.7 ng of the extracted fragment was labeled with ³²P (Multiprime™ DNA Labeling System; Amersham Corporation, Arlington Heights, IL). Unincorporated radioactivity was removed by column chromatography using a commercially available push column (NucTrap® column; Stratagene Cloning Systems, La Jolla, CA; see U.S. Patent No. 5,336,412). The blots were prehybridized for 3 hours at 65°C in a hybridization solution (ExpressHyb™ Hybridization Solution; Clontech Laboratories, Inc.) containing 1 mg of boiled salmon sperm DNA. 10.2 x 10⁶ cpm of probe and 1 mg of salmon sperm DNA were boiled for 5 minutes, iced, mixed with 10 ml of ExpressHyb™ solution, and added to the blots. The blots were incubated in the solution overnight at 65°C. Initial washes were done for 40 minutes in 2 x SSC, 0.1% SDS at room temperature, followed by a 40-minute wash at 50°C in 0.1 x SSC, 0.1% SDS with one change of wash solution. The washed blots were exposed to film at -80°C overnight, then washed again with 0.1 x SSC, 0.1% SDS at 65°C for 40 minutes to remove background and exposed overnight at -80°C. High expression was seen in pancreas, with lower expression in pituitary gland. The transcript size was approximately 1 kb.

Additional Northern blotting experiments were carried out essentially as disclosed above using a longer human zsig51 probe. Similar expression in pancreas and pituitary was seen, and a low-abundance transcript of approximately 4 kb was seen in human testis.

Example 3: Chromosomal Mapping

Human zsig51 was mapped to chromosome 11 using the commercially available GeneBridge 4 Radiation Hybrid Panel (Research

transformant. The transformant was streaked on an LB plate containing 175 µg/ml ampicillin and 25 µg/ml methicillin and incubated overnight at 37°C. The cDNA insert was sequenced and found to contain an open reading frame encoding 128 amino acids, including a putative 20 amino acid secretory peptide. The DNA and amino acid sequences are shown in SEQ ID NO:31 and NO:32, respectively.

Example 5: Chromosomal Mapping of Mouse Zsig51 Gene

The zsig51 gene was mapped in mouse using the commercially available mouse T31 whole genome radiation hybrid (WGRH) panel (Research Genetics, Inc., Huntsville, AL) and Map Manager QT linkage analysis program. The T31 WGRH panel contains PCRable DNAs from each of 100 radiation hybrid clones, plus two control DNAs (the 129aa donor and the A23 recipient). For mapping, 20-µl reactions were run essentially as disclosed in Example 3 using sense primer ZC18,588 (SEQ ID NO:40), 5' CCG TTT CTC CCG CTA CTA 3', and antisense primer ZC18,589 (SEQ ID NO:41), 5' GGG CCA ACC TCA TCT TCA 3'. The PCR cyclor conditions were as follows: an initial 5-minute denaturation at 94°C; 35 cycles of 1 minute denaturation at 94°C, 1 minute annealing at 66°C, and 90 seconds extension at 72°C; followed by a final extension of 7 minutes at 72°C. The reaction products were separated by electrophoresis on a 2% agarose gel (Life Technologies, Gaithersburg, MD).

At $P = 0.0001$, mouse zsig51 linked to the marker D19Mit68 with a LOD score of 8.2. D19Mit68 has been mapped at 6.0 cM on mouse chromosome 19. This is a known region of synteny or linkage conservation with the region of human chromosome 11 where the human form of zsig51 has been mapped.

Example 6: Rat Zsig51 cDNA

RNA extracted from rat pancreatic islet cells was reverse transcribed. The first strand cDNA reaction contained 16 µl of rat pancreatic islet cell poly d(T)-selected poly (A)⁺ mRNA at a concentration of 0.4 µg/ml, and 2 µl of 20 pmole/µl first strand primer (ZC6172; SEQ ID NO:33) containing an *Xho* I restriction site. The mixture was heated at 70°C for 3 minutes and cooled by chilling on ice. First strand cDNA synthesis was initiated by the addition of 8 µl of first strand buffer (5x SUPERScript™ buffer; Life Technologies, Gaithersburg, MD), 4 µl of 100 mM dithiothreitol,

and 2 μ l of a deoxynucleotide triphosphate (dNTP) solution containing 10 mM each of dTTP, dATP, dGTP and 5-methyl-dCTP (Pharmacia LKB Biotechnology, Piscataway, NJ) to the RNA-primer mixture. The reaction mixture was incubated at 45°C for 2 minutes, followed by the addition of 10 μ l of 200 U/ μ l RNase H⁻ reverse transcriptase (SUPERScript II®; Life Technologies). The efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 μ Ci of ³²P- α dCTP to a 5 μ l aliquot from one of the reaction mixtures to label the reaction for analysis. The reaction mixtures were incubated at 45°C for 50 minutes, then at 50°C for 10 minutes.

10 Unincorporated ³²P- α dCTP in the labeled reaction was removed by chromatography on a 400 pore size gel filtration column (Clontech Laboratories, Inc.). The unincorporated nucleotides and primers in the unlabeled first strand reactions were removed by chromatography on a 400 pore size gel filtration column. The length of labeled first strand cDNA was

15 determined by agarose gel electrophoresis.

The second strand reaction contained 100 μ l of the unlabeled first strand cDNA, 30 μ l of 5x polymerase I buffer (125 mM Tris-HCl, pH 7.5, 500 mM KCl, 25 mM MgCl₂, 50mM (NH₄)₂SO₄), 2.0 μ l of 100 mM dithiothreitol, 3.0 μ l of a solution containing 10 mM of each deoxynucleotide triphosphate, 7 μ l of 5 mM β -NAD, 2.0 μ l of 10 U/ μ l *E. coli* DNA ligase (New England Biolabs), 6 μ l of 10 U/ μ l *E. coli* DNA polymerase I (New England Biolabs, Beverly, MA), and 1.5 μ l of 2 U/ μ l RNase H (Life Technologies). A 10- μ l aliquot from one of the second strand synthesis reactions was labeled by the addition of 10 μ Ci ³²P- α dCTP to monitor the efficiency of second

20 strand synthesis. The reactions were incubated at 16°C for two hours, followed by the addition of 1 μ l of a 10 mM dNTP solution and 6.0 μ l T4 DNA polymerase (10 U/ μ l, Boehringer Mannheim, Indianapolis, IN) and incubated for an additional 10 minutes at 16°C. Unincorporated ³²P- α dCTP in the reaction mixture was removed by chromatography through a 400 pore size

30 gel filtration column before analysis by agarose gel electrophoresis. The reaction was terminated by the addition of 5 μ l 0.5 M EDTA and extraction with phenol/chloroform and chloroform followed by ethanol precipitation in the presence of 3.0 M Na acetate and 2 μ l of a dye-labeled carrier (Pellet Paint™ Co-Precipitant; Novagen, Madison, WI). The yield of cDNA was estimated to

35 be approximately 2 μ g from starting mRNA template of 10 μ g.

Eco RI adapters were ligated onto the 5' ends of the cDNA described above to enable cloning into an expression vector. A 10 μ l aliquot

precipitated, washed in 70% ethanol, air-dried and resuspended in 40 μ l water.

Following recovery from the low-melt agarose gel, the cDNA was cloned into the *Eco* RI and *Xho* I sites of a phagemid vector (pBluescript® II SK(+); Stratagene, La Jolla, CA) and electroporated into 5 DH10B cells.

1.5 million pfu from the rat pancreas cDNA library were plated onto 150 mm NZY plates at a density of 40,000 pfu/plate on electroporation-competent *E. coli* cells (XL1-Blue MRF' strain; Stratagene). Following 10 incubation at 37°C overnight, filter lifts were made using nylon membranes (Hybond-N™; Amersham Corporation, Arlington Heights, IL), according to the procedures provided by the manufacturer. The filters were processed by denaturation in a solution containing 1.5 M NaCl and 0.5 M NaOH for 7 minutes at room temperature. The filters were neutralized in 0.5 M Tris:HCl, 15 pH 7.2 for 7 minutes. Phage DNA was fixed onto the filters with 1,200 μ Joules of UV energy in a UV cross-linker (Stratagene). The filters were then washed with 0.25X SSC at 70°C to remove excess cellular debris.

A probe was generated by PCR using oligonucleotide primers ZC16763 (SEQ ID NO:34) and ZC16753 (SEQ ID NO:35) and plasmid 20 pSLSIG51-1 as a template. One μ l of a 1:100 dilution of the plasmid prep used to sequence pSLSIG51-1 was combined with 1 μ l of 20 pmole/ μ l ZC16763, 1 μ l of 20 pmole/ μ l ZC16753, and 45 μ l of a mixture of *Taq* DNA polymerase, salts, magnesium, and deoxynucleotide triphosphates (PCR Supermix; Life Technologies, Gaithersburg, MD). The amplification was 25 carried out at 94°C for 30 seconds followed by 35 cycles of 20 seconds at 94°C, 20 seconds at 55°C, and 1 minute at 68°C; followed by a final incubation at 68°C for 5 minutes. The probe was purified by gel electrophoresis.

The filters were pre-washed six times for 30 minutes in hot 30 0.25X SSC, 0.25% SDS, prehybridized overnight at 60°C in the same solution containing a 1/200 dilution of denatured herring sperm DNA, then hybridized to the probe over the weekend at 60°C in hybridization solution (containing, per liter: 250 ml 20X SSC (0.45 μ filtered), 50 ml 100X Denhardt's (5 Prime-3 Prime, Boulder, CO), 2 ml 0.5 M EDTA, 20 ml 10% 35 SDS (Research Genetics, Huntsville, AL), and water (Baxter, McGaw Park, IL) containing 20 μ l/ml sheared DNA (Research Genetics) denatured at 98°C for 10 minute and ~7.5 μ l probe denatured at 98°C for 4 minutes. Positives

Example 7: Zsig51 Adenovirus Vector Construction

The protein coding regions of human and mouse zsig51 were amplified by PCR using primers that added FseI and AsclI restriction sites at the 5' and 3' termini, respectively. PCR primers ZC17438 (SEQ ID NO:42) and ZC17439 (SEQ ID NO:43) were used with template plasmid containing the full-length human zsig51 cDNA. PCR primers ZC17950 (SEQ ID NO:44) and ZC17951 (SEQ ID NO:45) were used with template plasmid containing the full-length mouse zsig51 cDNA in a PCR reaction as follows: 95°C for 5 minutes; 15 cycles at 95°C for 1 min., 58°C for 1 min., and 72°C for 1.5 min.; 72°C for 7 min.; followed by a 4°C soak. The PCR reaction products were loaded onto a 1.2% (low melt) agarose (SeaPlaque GTG; FMC, Rockland, ME) gel in TAE buffer. The zsig51 PCR products were excised from the gel and purified using a spin column containing a silica gel membrane (QIAquick™ Gel Extraction Kit; Qiagen, Inc., Valencia, CA). The PCR products were then digested with FseI and AsclI, phenol/chloroform extracted, EtOH precipitated, and rehydrated in 20µl TE (Tris/EDTA pH 8). The 390bp (human) and 387bp (mouse) zsig51 fragments were then ligated into the FseI-AsclI sites of the vector pMT12-8 (Example 10, below) and transformed into DH10B competent cells by electroporation. Clones containing zsig51 inserts were identified by plasmid DNA miniprep followed by digestion with FseI and AsclI. A positive clone was sequenced to insure that there were no deletions or other anomalies in the construct. DNA was prepared using a commercially available kit (obtained from Qiagen, Inc.)

The zsig51 cDNA was released from the pTG12-8 vector using FseI and AsclI enzymes. The cDNA was isolated on a 1% low melt agarose gel and excised from the gel, and the gel slice was melted at 70°C, extracted twice with an equal volume of Tris-buffered phenol, and EtOH precipitated. The DNA was resuspended in 10µl H₂O. The cDNA was ligated into pACCMV shuttle vector (Microbix Biosystems, Inc. Ontario, Canada) in which the polylinker had been modified to include FseI and AsclI sites and transformed into *E. coli* host cells (Electromax DH10B™ cells; obtained from Life Technologies, Inc., Gaithersburg, MD) by electroporation. Clones containing zsig51 inserts were identified by plasmid DNA miniprep followed by digestion with FseI and AsclI. A large-scale preparation of DNA was made for transfection.

The zsig51-containing shuttle vectors were co-transfected with E1-deleted, adenovirus vector pJM17 (Microbix Biosystems, Inc.) into 293A

cells (Quantum Biotechnologies, Inc. Montreal, QC. Canada) that express the adenovirus E1 gene. The DNA was diluted up to a total volume of 50 μ l with sterile HBS (150mM NaCl, 20mM HEPES). In a separate tube, 20 μ l DOTAP (Boehringer Mannheim, 1mg/ml) was diluted to a total volume of 100 μ l with
5 HBS. The DNA was added to the DOTAP, mixed gently by pipeting up and down, and left at room temperature for 15 minutes. The media was removed from the 293A cells and washed with 5 ml serum-free MEMalpha containing 1mM sodium pyruvate, 0.1 mM MEM non-essential amino acids and 25mM HEPES buffer (all from Life Technologies, Inc.). 5 ml of serum-free MEM was
10 added to the 293A cells and held at 37°C. The DNA/lipid mixture was added drop-wise to the T25 flask of 293A cells, mixed gently, and incubated at 37°C for 4 hours. After 4 hours the media containing the DNA/lipid mixture was aspirated off and replaced with 5 ml complete MEM containing 5% fetal bovine serum. Virus propagation is conditional and is achieved only by
15 growing the E1-deleted virus in a cell line expressing the E1 gene.

Cells were maintained for 2-4 weeks until the recombination event occurred. (Recombinant virus is generated by homologous recombination of overlapping fragments of the viral genome in the pJM17 vector and the shuttle vector.) At that time, the host 293 cells were lysed by
20 the virus, forming plaques of dead cells. Within 3-5 days the entire monolayer was completely lysed. The medium containing the viral lysate was collected and any remaining intact cells were lysed by repeated freeze/thaw cycles and the cell debris pelleted by centrifugation.

The viral lysate was then plaque-purified according to the
25 method of Becker et al., *Meth. Cell Biol.* 43:161-189, 1994. Briefly, serial dilutions were prepared in DMEM containing 10% fetal bovine serum and 100 U/ml penicillin/streptomycin, plated on to monolayers of 293 cells, and incubated at 37°C for one hour. A melted 1.3% agarose/water solution was mixed with 2X DMEM (containing 4% FBS, 200 U/ml penicillin/streptomycin,
30 0.5 μ g/ml fungizone and 30 mg/ml phenol red), and 6 ml of the mixture was added to the virus-infected 293 cells followed by incubation at 37°C until plaques formed, 7-10 days. Single plaques were isolated, and the presence of the zsig51 insert was verified by PCR. The primers were ZC12700 (SEQ ID NO:48) and ZC12742 (SEQ ID NO:49). Amplification was carried out over
35 30 cycles of 94°C, 0.5 minute, 55°C, 0.5 minute, and 72°C, 0.5 minute; followed by a 10-minute extension at 72°C. One plaque each for human and

mouse zsig51 that had the expected size PCR product was used to do a primary amplification.

Ten 10-cm plates of nearly confluent (80-90%) 293A cells were set up 20 hours previously. Roughly 5% of the virus lysate from a plaque was added to each 10-cm plate and monitored for 48 to 72 hours looking for CPE (Cytopathic Effect) under the white light microscope. When all of the 293A cells showed CPE, this 1° stock lysate was collected and 3 freeze/thaw cycles performed.

For secondary (2°) amplification of zsig51 rAdV, 20 15-cm tissue culture dishes of 293A cells were prepared so that the cells were 80-90% confluent. All but 20 ml of 5% MEM media was removed, and each dish was inoculated with 300-500 ml of the 1° amplified rAdv lysate. After 48 hours the 293A cells were lysed from virus production, and the lysate was collected into 250-ml polypropylene centrifuge bottles.

To purify the recombinant virus, NP-40 detergent was added to a final concentration of 0.5% to the bottles of crude lysate to lyse all cells. Bottles were placed on a rotating platform for 10 min. agitating as fast as possible without the bottles falling over. The debris was pelleted by centrifugation at 20,000 X G for 15 minutes. The supernatant was transferred to 250-ml polycarbonate centrifuge bottles, and 0.5 volumes of 20% PEG8000/2.5M NaCl solution was added. The bottles were shaken overnight on ice. The bottles were centrifuged at 20,000 X G for 15 minutes, and supernatant was discarded into a bleach solution. Using a sterile cell scraper, the precipitate from 2 bottles was resuspended in 2.5 ml PBS. The resulting virus solution was placed in 2-ml microcentrifuge tubes and centrifuged at 14,000 X G for 10 minutes to remove any additional cell debris. The supernatant from the 2-ml microcentrifuge tubes was transferred into a 15-ml polypropylene snapcap tube and adjusted to a density of 1.34 g/ml with cesium chloride (CsCl). The volume of the virus solution was estimated, and 0.55 g/ml of CsCl was added. The CsCl was dissolved, and 1 ml of this solution weighed 1.34 g. The solution was transferred to polycarbonate thick-walled centrifuge tubes 3.2ml (Beckman) and spun at (348,000 X G) for 3-4 hours at 25°C. The virus formed a white band. Using wide-bore pipette tips, the virus band was collected.

The virus from the gradient had a large amount of CsCl which was removed before it could be used on cells. Pharmacia PD-10 columns prepacked with Sephadex G-25M (Pharmacia) were used to desalt the virus

preparation. The column was equilibrated with 20 ml of PBS. The virus was loaded and allowed to run into the column. 5 ml of PBS was added to the column, and fractions of 8-10 drops were collected. The optical densities of 1:50 dilutions of each fraction were determined at 260 nm on a spectrophotometer. A clear absorbance peak was present between fractions 7-12. These fractions were pooled, and the optical density (OD) of a 1:50 dilution was determined. OD was converted to virus concentration using the formula $(OD \text{ at } 260nm)(50)(1.1 \times 10^{12}) = \text{virions/ml}$. The human zsig51 rAdV concentration was 6.1×10^{12} virions/ml. The mouse zsig51 virus concentration was 9.2×10^{12} .

To store the virus, glycerol was added to the purified virus to a final concentration of 15%, mixed gently but effectively, and stored in aliquots at -80°C.

A protocol developed by Quantum Biotechnologies, Inc. (Montreal, Qc. Canada) was followed to measure recombinant virus infectivity. Briefly, two 96-well tissue culture plates were seeded with 1×10^4 293A cells per well in MEM containing 2% fetal bovine serum for each recombinant virus to be assayed. After 24 hours, 10-fold dilutions of each virus from 1×10^{-2} to 1×10^{-14} were made in MEM containing 2% fetal bovine serum. 100µl of each dilution was placed in each of 20 wells. After 5 days at 37°C, wells were read either positive or negative for CPE, and a value for "Plaque Forming Units/ml" (PFU) was calculated.

TCID₅₀ formulation used was as per Quantum Biotechnologies, Inc., above. The titer (T) was determined from a plate where virus used was diluted from 10^{-2} to 10^{-14} , and read 5 days after the infection. At each dilution a ratio (R) of positive wells for CPE per the total number of wells was determined.

Example 8: Adenovirus Administration of Zsig51 to Normal Mice

Human and mouse zsig51s were administered to mice using adenovirus vectors containing the coding region of the human gene (zsig51h; SEQ ID NO:1) or its mouse orthologue (zsig51m; SEQ ID NO:31). The adenovirus vectors were injected intravenously into C57Bl/6 mice according to the experimental design shown in Table 5. Blood was drawn and analyzed on day 12 and then again on day 21 of each experiment. All mice received bromodeoxyuridin (BrdU) in their drinking water three days before sacrifice. Animals were sacrificed on day 21. Parameters measured included weight

change, complete blood counts, serum chemistries, histology, organ weights, and cell proliferation measured by BrdU incorporation.

Table 5

5	Group 1	zsig51 rAdV 1 x 10 ¹¹ particles/dose 10 females, 10 males
10	Group 2	null AdV control 1 x 10 ¹¹ particles/dose 10 females, 10 males
15	Group 3	no treatment 5 females, 5 males

Female glucose levels were higher in zsig51h experimental groups than in null virus control groups. Both male and female glucose levels were lower in zsig51m experimental groups than in null virus control groups. This lowered glucose was seen in zsig51m mice both in a fasting state and in a well-fed state.

The liver weights of both males and females in zsig51m experimental groups were higher than in null virus control groups.

25 Example 9: In Situ Hybridization

Fresh tissue was fixed in 4% paraformaldehyde at 4°C overnight. Tissue was embedded in paraffin using a standard protocol with the exception that Histoclear (National Diagnostics, Atlanta, GA) was substituted for xylene. 5-10 micron sections were mounted onto slides (Superfrost™ Plus; VWR Scientific, West Chester, PA), and the slides were baked at 37°C for 4 hours, then stored at 4°C. Alternatively, fixed and sectioned tissues were obtained from commercial sources. The slides were de-waxed in Histoclear and rehydrated through an ethanol series. They were then air-dried and stored at -20°C.

35 For *in situ* hybridization, slides were allowed to come to room temperature, washed 3 times for 5 minutes each in phosphate-buffered saline containing 0.1% polyoxyethylenesorbitan monolaurate (Tween 20) (PBT),

then incubated at 37°C in PBT with proteinase K at a concentration of 2-100 µg/ml. Slides were rinsed twice for 5 minutes in PBT, fixed again in 4% paraformaldehyde for 20 minutes at room temperature, and rinsed twice for 5 minutes in PBT. Sections were acetylated by dipping the slides into a mixture of 197 ml deionized water, 2.6 ml triethanolamine, and 350 µl hydrochloric acid. 500 µl of acetic anhydride was added drop by drop while stirring, and the incubation of the slides was continued in this mixture at room temperature for 10 minutes. Slides were rinsed twice for 5 minutes in PBT, then dehydrated through a methanol series and air-dried.

The sections were hybridized with an *in vitro*-transcribed digoxigenin-labeled RNA antisense zsig51 probe representing the complete protein coding region of the gene. Human tissues were probed with an antisense to the human gene (SEQ ID NO:2 human coding region only) and mouse tissues were probed with an antisense to the mouse orthologue (SEQ ID NO:32 mouse coding region only). The probes were used at a concentration of 200 ng to 1 µg/ml in 50% formamide, 10% dextran sulphate, 5x SSC, 5x Denhardt's solution, 250 µg/ml yeast tRNA, 500 µg/ml salmon sperm DNA, and 50 µg/ml heparin. Hybridization was done overnight at 60-72°C. The slides were washed, using solutions preheated at 60-72°C, in 50% formamide, 2X SSC, once for 15 minutes; then in a fresh wash for 30 minutes; and finally in 25% formamide, 1X SSC, 0.5X PBS for 30 minutes. Slides were then rinsed twice in PBT at room temperature for 5 minutes.

The sections were blocked in 5% nonfat dried milk, 4x SSC, and 0.1% Tween 20 (blocking solution) with 5% normal rabbit or goat serum added for 1 hour at room temperature. Slides were then rinsed in PBT at room temperature three times for 5 minutes. Sheep anti-digoxigenin antibody (Boehringer Mannheim, Indianapolis, IN) was diluted 1:1000 in blocking solution, added to slides, and incubated for 30 minutes at room temperature. Slides were washed four times for 15 minutes each in blocking solution. Biotinylated rabbit-anti-sheep antibody (Vector Laboratories, Burlingame, CA) was diluted 1:200 in blocking solution with 7.5% normal mouse serum added, and allowed to incubate at room temperature at least 30 minutes before being added to slides and incubated for an additional 30 minutes at room temperature. Slides were then washed two times for 5 minutes each in blocking solution. Avidin and biotinylated peroxidase (Vectastain® ABC-AP Kit; Vector Laboratories) were prepared according to the manufacturer's instructions before being added to slides, which were then incubated for 30

FseI and AseI (Boehringer Mannheim), ethanol precipitated, and ligated into pMT12-8 that was previously digested with FseI and AseI. The pMT12-8 plasmid, designed for expression of a gene of interest in transgenic mice, contains an expression cassette flanked by 10 kb of MT-1 5' DNA and 7 kb of MT-1 3' DNA. The expression cassette comprises the mouse MT-1 promoter, a rat insulin II intron, a polylinker for the insertion of the desired clone, and the human growth hormone poly A sequence.

About one microliter of each of the ligation mixtures was electroporated into *E. coli* host cells (Electromax DH10B™ cells; obtained from Life Technologies, Inc., Gaithersburg, MD) according to supplier's directions and plated onto LB plates containing 100 µg/ml ampicillin, and incubated overnight. Colonies were picked and grown in LB medium containing 100 µg/ml ampicillin. Miniprep DNA was prepared from the picked clones and screened for the zsig51 human or mouse insert by restriction digestion with EcoRI, and subsequent agarose gel electrophoresis. Maxipreps of the correct pMT-zsig51 constructs were prepared. A SalI fragment containing with 5' and 3' flanking sequences, the MT-1 promoter, the rat insulin II intron, zsig51 human or mouse cDNA, and the human growth hormone poly A sequence was prepared and used for microinjection into fertilized mouse oocytes to generate transgenic founder animals. The original oocytes and the sperm used to fertilize them were from F1 hybrids of C3H and C57Bl/6 mice. In subsequent generations, the mice were mated at every generation to C57Bl/6 mice. The human transgene was designated MTzsig51h, while the mouse transgene was designated MTzsig51m.

Five male and five female transgenic mice carrying MTzsig51h were identified. The expression level of the transgene in the liver of each mouse was quantified by real-time RT-PCR on an ABI Prism 7700 Sequence Detector (Perkin-Elmer). This analysis indicated that none of the males had a measurable level of expression. The expression profile of the females was: 2 very high expressors (greater than 10,000 mRNA molecules/liver cell); 1 high expressor (greater than 2,000 mRNA molecules/liver cell); 1 medium expressor (approximately 600 mRNA molecules/liver cell); and 1 low expressor (approximately 300 mRNA molecules/liver cell).

Two male and ten female transgenic mice carrying MTzsig51m were identified. The expression level of the transgen in the liver of each mouse was quantifi d as above. Neither of the males had a measurable level of expression. The expression profile of the females was: 5 very high

expressors (greater than 10,000 mRNA molecules/liver cell); 1 high expressor (greater than 2,000 mRNA molecules/liver cell); 1 medium expressor (approximately 1,100 mRNA molecules/liver cell); 1 low expressor (approximately 300 mRNA molecules/liver cell); and 1 below the measurable level of expression.

Parameters measured included weight change, fertility, complete blood counts, serum chemistries, histology, organ weights and cell proliferation measured by incorporation of bromodeoxyuridine (BrdU). All mice received BrdU in their drinking water three days before sacrifice.

For the MTzsig51h transgenics, male animals were sacrificed at approximately two months of age, while females were sacrificed at approximately 5 months, and tissues were collected for histological analysis. Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 3 microns, and stained with hematoxylin and eosin. The slides were examined and scored by a board-certified veterinary pathologist. Female mice were found to have scattered small areas of mineralization in the heart, lung, skeletal muscle, and the growth plate of the femur.

In the second generation of offspring that arose from matings to C57Bl/6 mice, the highest-expressing line of MTzsig51h mice gave rise to transgenic females that displayed severe hair loss at weaning.

MTzsig51M animals were sacrificed at approximately six months of age. Tissues were collected for histological analysis, fixed, examined, and scored as above. The highest expressing female MTzsig51m mouse was infertile.

Example 11: Baculovirus expression

C-terminal Glu-Glu tagged human zsig51 is expressed in Sf9 cells using a baculovirus vector. The tagged protein comprises the peptide tag shown in (SEQ ID NO:46). The zsig51cee sequence (as a EcoRI-BamHI fragment) is inserted into a modified pFastBac™ expression vector (Life Technologies) containing the late activating Basic Protein promoter. About 90 nanograms of the zsig51cee insert and about 150 ng of the digested vector are ligated overnight. The ligation mix is diluted 3-fold in TE (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA), and 4 fmol of the diluted ligation mix is transformed into competent *E. coli* cells (Library Efficiency DH5α™ competent cells; Life Technologies, Gaithersburg, MD) according to the manufacturer's directions by heat shock for 45 seconds in a 42°C waterbath.

The ligated DNA is diluted in 450 μ l of SOC media (2% Bacto Tryptone, 0.5% Bacto Yeast Extract, 10 ml 1M NaCl, 1.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, and 20 mM glucose) and plated onto LB plates containing 100 μ g/ml ampicillin. Clones are analyzed by restriction digests, and 1 μ l of a positive
5 clone is transformed into 20 μ l *E. coli* cells (Max Efficiency DH10Bac™ competent cells; Life Technologies) according to the manufacturer's instructions, by heat shock for 45 seconds in a 42°C waterbath. The ligated DNA is diluted in 980 μ l SOC media and plated onto Luria Agar plates containing 50 μ g/ml kanamycin, 7 μ g/ml gentamycin, 10 μ g/ml tetracycline,
10 IPTG and Bluo Gal. The cells are incubated for 48 hours at 37°C. A color selection is used to identify those cells having virus that has incorporated into the plasmid (referred to as a "bacmid"). Those colonies, which are white in color, are picked for analysis. Bacmid DNA is isolated from positive colonies using commercially available reagents and equipment (QIAprep® 8 Miniprep
15 Kit and QIAvac vacuum manifold; Qiagen, Inc., Valencia, CA) according the manufacturer's directions. Clones are screened for the correct insert by amplifying DNA using primers to the Basic Protein promoter and to the SV40 terminus via PCR. Those having the correct insert are used to transfect *Spodoptera frugiperda* (Sf9) cells.

20 Sf9 cells are seeded at 5×10^6 cells per 35 mm plate and allowed to attach for 1 hour at 27°C. Five microliters of bacmid DNA is diluted with 100 μ l serum-free media (Sf-900 II SFM; Life Technologies). Six μ l of a 1:1.5 (M/M) liposome formulation of the cationic lipid N, N', N'', N'''-tetramethyl-N, N', N'', N'''-tetrapalmitylspermine and dioleoyl
25 phosphatidylethanolamine in membrane-filtered water (CellFECTIN™ reagent; Life Technologies) is diluted with 100 μ l Sf-900 II SFM. The bacmid DNA and lipid solutions are gently mixed and incubated 30-45 minutes at room temperature. The media from one plate of cells are aspirated, the cells are washed 1X with 2 ml fresh media. Eight hundred microliters of Sf-900 II
30 SFM is added to the lipid-DNA mixture. The wash media is aspirated and the DNA-lipid mix added to the cells. The cells are incubated at 27°C for 4-5 hours. The DNA-lipid mix is aspirated and 2 ml of Sf-900 II media containing penicillin/streptomycin is added to each plate. The plates are incubated at 27°C, 90% humidity, for 96 after which the virus is harvested.

35 Sf9 cells are grown in 50 ml Sf-900 II SFM in a 200 ml shake flask to an approximate density of $0.41-0.52 \times 10^6$ cells/ml. They are then transfected with 100 μ l of the virus stock from above and incubated at 27°C

for 2-3 days after which time the virus is harvested. The titer for AcCSCF1 is 1.7×10^7 pfu/ml and for AcCSNF1 it is 2.6×10^7 . To scale up, 1.5×10^8 SF9 cells/ml are added to five liters of SF 900 II SFM and grown for 91 hours. The cells are then transfected with the harvested virus (MOI 0.2) and
5 incubated as above for 71 hours.

Example 12: Protein Purification and Analysis

Glu-Glu tagged zsig51 protein (zsig51cee) was produced in baculovirus infected cells essentially as disclosed above, and the protein was
10 purified from cell-conditioned media by affinity chromatography. A 100 ml bed volume of immobilized protein G (protein G-Sepharose®; Pharmacia Biotech) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit. The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA; Sigma Chemical
15 Co., St. Louis, MO), and an equal volume of anti-glu-glu antibody solution containing 900 mg of antibody was added. After an overnight incubation at 4°C, unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA as described above. The resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimidate-2HCl
20 (Pierce, Rockford, IL), dissolved in TEA, was added to a final concentration of 36 mg/ml of gel. The gel was rocked at room temperature for 45 minutes, and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 minutes at room temperature with 5 volumes of 20 mM ethanolamine in 200 mM TEA.
25 The gel was washed with 5 volumes of PBS containing 0.02% sodium azide and stored in this solution at 4°C.

Unless otherwise noted, all purification steps were carried out at 4°C. A mixture of protease inhibitors was added to a 2 liter sample of conditioned media from baculovirus-infected Sf9 cells to final concentrations
30 of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co., St. Louis, MO), 0.001 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride (Pefabloc®; Boehringer-Mannheim). The sample was centrifuged at 10,000 rpm for 30 min at 4°C in a Beckman
35 JLA-10.5 rotor (Beckman Instruments) in a Beckman Avanti J25I centrifuge (Beckman Instruments) to remove cell debris. To the supernatant fraction was added a 50.0 ml sample of anti-EE Sepharose, prepared as described

above, and the mixture was gently agitated on a Wheaton (Millville, NJ) roller culture apparatus for 18.0 h at 4°C.

The mixture was poured into a 5.0 x 20.0 cm column (Econo-Column®; Bio-Rad Laboratories, Hercules, CA), and the gel was washed
5 with 30 column volumes of phosphate buffered saline (PBS). The unretained flow-through fraction was discarded. Once the absorbance of the effluent at 280 nM was less than 0.05, flow through the column was reduced to zero and the anti-EE Sepharose gel was washed with 2.0 column volumes of PBS containing 0.2 mg/ml of EE peptide having the sequence Glu-Tyr-Met-Pro-
10 Val-Asp (SEQ ID NO:47) (AnaSpec, San Jose, CA). After 1.0 hour at 4°C, flow was resumed and the eluted protein was collected. This fraction was referred to as the peptide elution. The anti-EE Sepharose gel was washed with 2.0 column volumes of 0.1 M glycine, pH 2.5, and the glycine wash was collected separately. The pH of the glycine-eluted fraction was adjusted to
15 7.0 by the addition of a small volume of 10X PBS and stored at 4°C.

The peptide elution was concentrated to 5.0 ml using a 5,000 molecular weight cutoff membrane concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions. The concentrated peptide elution was separated from free peptide by chromatography on a 1.5 x 50 cm
20 Sephadex® G-50 (Pharmacia Biotech) column equilibrated in PBS at a flow rate of 1.0 ml/min using a commercially available HPLC system (BioCad™/Sprint™ HPLC system; PerSeptive BioSystems, Framingham, MA). Two-ml fractions were collected and the absorbance at 280 nM was monitored. The first peak of material absorbing at 280 nM and eluting near
25 the void volume of the column was collected. This material represented purified zsig51cee. The material was aliquoted and stored at -80°C.

The N-terminal peptide of the recombinant zsig51cee was identified by mass spectrometry. Two forms were found. The first had a mass of 2000.8, which indicated an N-terminal peptide with a pyro-glutamic acid instead of glutamine (residue 1 of SEQ ID NO:2). The second form had
30 a mass of 3038, corresponding to the first peptide with glycosylation consisting of 2HexNAc, 3Hex, and 1 deoxyhex.

Example 13: Expression of Zsig51 in Mammalian Cells

35 A mammalian expression vector was constructed with the dihydrofolate reductase gene under control of the SV40 early promoter and SV40 polyadenylation site, and a cloning site to insert the gene of interest

under control of the mouse MT-1 promoter and the hGH polyadenylation site. The expression vector was designated pZP-9 and was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on February 20, 1998 under Accession Number 98668. To facilitate purification of the protein of interest, the pZP-9 vector was modified by addition of the tPA leader sequence (U.S. Patent 5,641,655, incorporated herein by reference) and a GluGlu tag (SEQ ID NO:46) between the MT-1 promoter and hGH terminator. Expression results in an N-terminally tagged fusion protein comprising the tPA leader. The N-terminally tagged vector was designated pZP9NEE.

BHK570 cells (ATCC CRL 10314) were plated on 10-cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluency overnight. Unless otherwise specified the cells were handled using standard aseptic technique, grown at 37°C, 5% CO₂, in water-jacketed incubators (Model 3110; Forma Scientific, Marietta, OH), and with the following media: DMEM (High Glucose, #11965-092; Life Technologies, Gaithersburg, MD), 5% Fetal Bovine Serum (Hyclone, Logan, UT), 1% L-Glutamine (JRH Biosciences, Lenexa, KS), 1% sodium pyruvate (Life Technologies). The cells were transfected with plasmid pZP9/zsig51NEE, using a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium-trifluoroacetate and the neutral lipid dioleoyl phosphatidylethanolamine in membrane-filtered water (Lipofectamine™ Reagent; Life Technologies), in a serum-free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5 mg/ml insulin, 1 mg/ml fetuin, 1% L-Glutamine (JRH #59202-77P), 1% sodium pyruvate. 16 µg of plasmid was diluted in a 15-ml tube with 640 µl SF media, and in a separate tube, 35 µl of Lipofectamine™ was mixed with 605 µl of SF media. The Lipofectamine™ mix was added to the DNA mix and allowed to incubate approximately 30 minutes at room temperature. Five ml of SF medium was added to the DNA:Lipofectamine™ mixture. The cells were rinsed once with 5 ml of SF medium, aspirated, and the DNA:Lipofectamine™ mixture was added. The cells were incubated at 37°C for five hours, then 6.4 ml of 10% FBS/DMEM medium was added to the plate. The plate was incubated at 37°C overnight, and the DNA:Lipofectamine™ mixture was replaced with fresh medium the next day. On day 2 after transfection, the cells were split into transfection media (standard media plus 1 µM methotrexate) in 150-mm plates at 1:50, 1:100,

and 1:200. The plates were re-fed at day 5 following transfection with fresh selection medium. Once resistant colonies reached 3-4 mm in diameter, a plate containing 70 to 150 colonies was selected for immunoassay.

5 The plate of cells was rinsed with 10 ml SF media, then 5 ml SF media is added, followed by a nylon mesh, then a notched nitrocellulose filter, both pre-soaked in SF media. Matching alignment marks were made on the plate, and it was incubated for approximately 5 hours at 37°C. The filter and mesh were removed, and the cells were re-fed standard media plus penicillin-streptomycin-neomycin antibiotic mix (Life Technologies) and incubated at
10 37°C. The filter was incubated with anti-GluGlu antibody conjugated to horseradish peroxidase, at 1:5000 dilution, in 2.5% non-fat dry milk Western A buffer for 1 hour at room temperature on a rotating shaker. The filter was washed three times at room temperature in PBS plus 0.01% Tween 20, 15 minutes per wash. The filter was developed with commercially available
15 reagents (ECL™ Western blotting detection reagents; Amersham Life Science Inc., Arlington Heights, IL) according to the manufacturer's directions and exposed to film (Hyperfilm™ ECL, Amersham) for approximately 5 minutes. The alignment marks on the filter were transferred to the film.

20 The film was aligned with the marks on the plate of cells for selection of colonies with optimal signals. The colonies were circled and the media was removed from the plate. Sterile 3-mm cloning discs (PGM Scientific Corporation #62-6151-12) soaked in trypsin were placed on the colonies, then transferred to 200 µl of selection media in a 96-well dish. A
25 series of seven, two-fold serial dilutions was carried out with the cells recovered from the disc. The cells were grown for one week at 37°C, then expanded by selecting the well with the lowest dilution of cells at confluency for each clone for trypsinization and transferring it to a 12 well dish containing selection media.

30 The clones were expanded directly from the 12-well dish to two T75 flasks for each clone. One flask was maintained in selection media at 37°C. The other flask was used for Western blot analysis of the clones. The flask was first grown to confluency, then the medium was changed to SF, allowed to incubate for two days at 37°C, harvested, and filtered at 0.22 µm.
35 This flask is discarded after harvest.

The conditioned medium was concentrated 10-fold by ultrafiltration, and analyzed by Western blot. Three clones producing the

highest levels of protein were selected and samples were frozen. The clones are pooled and transferred for large scale culture.

Example 14: Expression analysis by quantitative RT-PCR

5 The expression level of zsig51 mRNA in a variety of human and mouse tissues was quantified by real-time PCR (RT-PCR) on an ABI Prism 7700 Sequence Detector (Perkin-Elmer, Norwalk, CT) following the manufacturer's protocols. Total RNA was prepared from fresh mouse tissues using a commercially available kit (RNeasy® kit; Qiagen). Human total RNA
10 samples were purchased from a variety of commercial sources (Invitrogen, Clontech).

 Expression of zsig51 mRNA in the pancreas of diabetic NOD mice was found to be significantly higher than in the pancreas of non-diabetic NOD mice. Expression of zsig51 in the pancreas of fasted mice was found to
15 be lower than in the pancreas of well-fed mice. Expression of zsig51 in the mouse eye was found to be approximately 50-fold higher than expression in normal pancreas.

 From the foregoing, it will be appreciated that, although specific
20 embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. An isolated polypeptide comprising at least 15 consecutive amino acid residues of SEQ ID NO:2.
2. An isolated polypeptide that is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2, said polypeptide comprising cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2; a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2; and beta strand-like regions corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2.
3. The isolated polypeptide according to claim 2 further comprising cysteine residues at positions corresponding to residues 25, 65, 80, and 101 of SEQ ID NO:2.
4. The isolated polypeptide according to claim 2 wherein amino acid residues corresponding to residues 8, 11, 12, 14, 29, 30, 32, 34, 43, 44, 60, 63, 64, 65, 71, 74, 80, 90, 91, 93, and 94 of SEQ ID NO:2 are Cys, His, Pro, Asn, His, Val, Gln, Cys, Phe, Pro, Thr, Ser, Gln, Cys, Leu, Val, Cys, Ile, Phe, Ala, and Arg, respectively; and an amino acid residue corresponding to residue 75 of SEQ ID NO:2 is Lys or Arg.
5. The isolated polypeptide according to claim 2 wherein said polypeptide is at least 95% identical to residues 1 through 106 of SEQ ID NO:2.
6. The isolated polypeptide according to claim 2 comprising residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29.
7. The isolated polypeptide according to claim 2, covalently linked to an affinity tag.
8. The isolated polypeptide according to claim 2, covalently linked to an immunoglobulin constant region.

9. An isolated protein comprising a first polypeptide according to any of claims 2-8 complexed to a second polypeptide, wherein said protein modulates cell proliferation, differentiation, or metabolism.

10. The isolated protein according to claim 9 wherein said protein is a heterodimer.

11. The isolated protein according to claim 10 wherein said second polypeptide is a glycoprotein hormone common alpha subunit.

12. The isolated protein according to claim 9 wherein said first polypeptide comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29.

13. The isolated protein according to claim 9 wherein said protein is a homodimer.

14. The isolated protein according to claim 13 wherein each of said first and second polypeptides comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29.

15. An isolated polynucleotide encoding a polypeptide according to any of claims 2-8.

16. The isolated polynucleotide according to claim 15 comprising a sequence of nucleotides as shown in SEQ ID NO:4 from nucleotide 70 through nucleotide 387 or SEQ ID NO:30 from nucleotide 70 through nucleotide 387.

17. The isolated polynucleotide according to claim 18 comprising a sequence of nucleotides as shown in SEQ ID NO:1 from nucleotide 125 through nucleotide 442.

18. The isolated polynucleotide according to claim 15 wherein said polynucleotide is from 318 to 1000 nucleotides in length.

obtaining a genetic sample from a patient;

incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product;

comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.

28. An oligonucleotide probe or primer comprising 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:4 or a sequence complementary to SEQ ID NO:4.

AMENDED CLAIMS

[received by the International Bureau on 12 July 1999 (12.07.99);
original claims 17 and 20 amended; remaining claims unchanged (2 pages)]

9. An isolated protein comprising a first polypeptid according to any of claims 2-8 complexed to a second polypeptide, wherein said protein modulates cell proliferation, differentiation, or metabolism.

10. The isolated protein according to claim 9 wherein said protein is a heterodimer.

11. The isolated protein according to claim 10 wherein said second polypeptide is a glycoprotein hormone common alpha subunit.

12. The isolated protein according to claim 9 wherein said first polypeptide comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29.

13. The isolated protein according to claim 9 wherein said protein is a homodimer.

14. The isolated protein according to claim 13 wherein each of said first and second polypeptides comprises residue 1 through residue 106 of SEQ ID NO:2 or residue 1 through residue 106 of SEQ ID NO:29.

15. An isolated polynucleotide encoding a polypeptide according to any of claims 2-8.

16. The isolated polynucleotide according to claim 15 comprising a sequence of nucleotides as shown in SEQ ID NO:4 from nucleotide 70 through nucleotide 387 or SEQ ID NO:30 from nucleotide 70 through nucleotide 387.

17. The isolated polynucleotide according to claim 15 comprising a sequence of nucleotides as shown in SEQ ID NO:1 from nucleotide 125 through nucleotide 442.

18. The isolated polynucleotide according to claim 15 wherein said polynucleotide is from 318 to 1000 nucleotides in length.

19. The isolated polynucleotide according to claim 15 wherein said polynucleotide is DNA.

20. An expression vector comprising the following operably linked elements:

a transcription promoter;

a DNA segment encoding a polypeptide according to any of claims 2-8;

and

a transcription terminator.

21. The expression vector according to claim 20 wherein said DNA segment further encodes a secretory peptide operably linked to said polypeptide.

22. The expression vector according to claim 21 wherein said DNA segment encodes residue -23 through residue 106 of SEQ ID NO:2 or residue -23 through residue 106 of SEQ ID NO:29.

23. A cultured cell into which has been introduced an expression vector according to claim 20, wherein said cell expresses the polypeptide encoded by the DNA segment.

24. A pharmaceutical composition comprising a polypeptide according to any of claims 2-8 in combination with a pharmaceutically acceptable vehicle.

25. A method of producing a polypeptide comprising:
culturing a cell into which has been introduced an expression vector according to claim 20, whereby said cell expresses the polypeptide encoded by the DNA segment; and
recovering the expressed polypeptide.

26. An antibody that specifically binds to an epitope of a polypeptide according to claim 2.

27. A method for detecting a genetic abnormality in a patient, comprising:

19. The isolated polynucleotide according to claim 15 wherein said polynucleotide is DNA.

20. An expression vector comprising the following operably linked elements:

a transcription promoter;

a DNA segment encoding a polypeptide according to any of claims 2-8;

and

a transcription terminator.

21. The expression vector according to claim 20 wherein said DNA segment further encodes a secretory peptide operably linked to said polypeptide.

22. The expression vector according to claim 21 wherein said DNA segment encodes residue -23 through residue 106 of SEQ ID NO:2 or residue -23 through residue 106 of SEQ ID NO:29.

23. A cultured cell into which has been introduced an expression vector according to claim 20, wherein said cell expresses the polypeptide encoded by the DNA segment.

24. A pharmaceutical composition comprising a polypeptide according to any of claims 2-8 in combination with a pharmaceutically acceptable vehicle.

25. A method of producing a polypeptide comprising:
culturing a cell into which has been introduced an expression vector according to claim 20, whereby said cell expresses the polypeptide encoded by the DNA segment; and
recovering the expressed polypeptide.

26. An antibody that specifically binds to an epitope of a polypeptide according to claim 2.

27. A method for detecting a genetic abnormality in a patient, comprising:


1/3

Hydrophobic		Hydrophilic				
-3	-2	-1	0	1	2	3
1	0.20			M==		
2	0.34			P===		
3	0.16			M==		
4	-0.03			A		
5	-0.31			===S		
6	-0.77			=====P		
7	-1.27			=====Q		
8	-1.60			=====T		
9	-1.83			=====L		
10	-1.78			=====V		
11	-1.83			=====L		
12	-1.62			=====Y		
13	-1.48			=====L		
14	-1.25			=====L		
15	-0.45			=====V		
16	-0.28			===L		
17	-0.55			=====A		
18	-0.47			=====V		
19	-0.18			==T		
20	0.38			E=====		
21	-0.20			==A		
22	-0.37			====W		
23	-0.10			=G		
24	-0.10			=Q		
25	-0.13			=E		
26	-0.80			=====A		
27	-0.80			=====V		
28	-0.85			=====I		
29	-0.63			=====P		
30	-0.63			=====G		
31	-1.05			=====C		
32	-0.85			=====H		
33	-1.02			=====L		
34	-0.78			=====H		
35	-0.95			=====P		
36	-0.45			====F		
37	0.02			N		
38	0.48			V=====		
39	1.23			T=====		
40	1.33			V=====		
41	1.58			R=====		
42	1.02			S=====		
43	0.80			D=====		
44	0.33			R===		
45	-0.17			==Q		
46	-0.15			=G		
47	-0.23			==T		
48	-0.42			====C		
49	-0.33			====Q		
50	-0.33			====G		
51	-0.42			====S		
52	-0.63			====H		

2/3

53	-0.80	=====V
54	-0.55	=====A
55	-0.55	=====Q
56	-0.75	=====A
57	-0.17	==C
58	0.05	V=
59	0.35	G=====
60	0.27	H=====
61	-0.07	=C
62	0.10	E=
63	-0.35	====S
64	0.10	S=
65	0.07	A=
66	0.20	F==
67	0.37	P=====
68	0.07	S=
69	-0.23	==R
70	-0.82	=====Y
71	-0.78	=====S
72	-0.83	=====V
73	-0.57	=====L
74	0.23	V==
75	0.40	A=====
76	0.52	S=====
77	0.17	G==
78	0.10	Y=
79	0.13	R=
80	-0.62	=====H
81	-0.48	=====N
82	-0.48	=====I
83	-0.35	====T
84	-0.45	=====S
85	-1.07	=====V
86	-1.12	=====S
87	-1.12	=====Q
88	-1.15	=====C
89	-1.28	=====C
90	-0.62	=====t
91	0.45	I=====
92	0.50	S=====
93	0.95	G=====
94	0.70	L=====
95	1.03	K=====
96	0.23	K==
97	-0.23	==V
98	-0.15	=K
99	-0.90	=====V
100	-0.65	=====Q
101	-0.63	=====L
102	0.17	Q==
103	0.63	C=====
104	1.30	V=====
105	2.05	G=====
106	1.75	S=====
107	2.20	R=====

3/3



SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> NOVEL CYSTINE KNOT PROTEIN AND MATERIALS
AND METHODS FOR MAKING IT

<130> 97-65PC

<150> US 09/023,570

<151> 1998-02-13

<160> 49

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 746

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (56)...(442)

<221> sig_peptide

<222> (56)...(127)

<400> 1

ccagcaggag gcacaggaaa actgcaagcc gctctgttcc tgggcctcgg aagtg atg	58
Met	

cct atg gcg tcc cct caa acc ctg gtc ctc tat ctg ctg gtc ctg gca	106
Pro Met Ala Ser Pro Gln Thr Leu Val Leu Tyr Leu Leu Val Leu Ala	
-20 -15 -10	

gtc act gaa gcc tgg ggc cag gag gca gtc atc cca ggc tgc cac ttg	154
Val Thr Glu Ala Trp Gly Gln Glu Ala Val Ile Pro Gly Cys His Leu	
-5 1 5 10	

cac ccc ttc aat gtg aca gtg cga agt gac cgc caa ggc acc tgc cag	202
His Pro Phe Asn Val Thr Val Arg Ser Asp Arg Gln Gly Thr Cys Gln	
15 20 25	

ggc tcc cac gtg gca cag gcc tgt gtg ggc cac tgt gag tcc agc gcc 250
Gly Ser His Val Ala Gln Ala Cys Val Gly His Cys Glu Ser Ser Ala
30 35 40

ttc cct tct cgg tac tct gtg ctg gtg gcc agt ggt tac cga cac aac 298
Phe Pro Ser Arg Tyr Ser Val Leu Val Ala Ser Gly Tyr Arg His Asn
45 50 55

atc acc tcc gtc tct cag tgc tgc acc atc agt ggc ctg aag aag gtc 346
Ile Thr Ser Val Ser Gln Cys Cys Thr Ile Ser Gly Leu Lys Lys Val
60 65 70

aaa gta cag ctg cag tgt gtg ggg agc cgg agg gag gag ctc gag atc 394
Lys Val Gln Leu Gln Cys Val Gly Ser Arg Arg Glu Glu Leu Glu Ile
75 80 85 90

ttc acg gcc agg gcc tgc cag tgt gac atg tgt cgc etc tct cgc tac 442
Phe Thr Ala Arg Ala Cys Gln Cys Asp Met Cys Arg Leu Ser Arg Tyr
95 100 105

tag cccatcctct cccctcttc ctcccctggg tcacagggt tgacattctg 495

```
gtgggggaaa cctgtgttca agattcaaaa actggaagga gctccagccc tgatggttac    555
ttgctatgga atttttttta ataaggggag ggttggtcca gctttgatcc tttgtaagat    615
tttgtgactg tcacctgaga agaggggagt ttctgcttct tccctgcctc tgcctggccc    675
ttctaaacca atctttcatc attttacttc cctctttgcc cttacccta aataaagcaa    735
gcagttcttg a                                     746
```

```
<210> 2
<211> 129
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SIGNAL  
<222> (1)...(23)
```

<400> 2
Met Pro Met Ala Ser Pro Gln Thr Leu Val Leu Tyr Leu Leu Val Leu
-20 -15 -10
Ala Val Thr Glu Ala Trp Gly Gln Glu Ala Val Ile Pro Gly Cys His
-5 1 5

Leu His Pro Phe Asn Val Thr Val Arg Ser Asp Arg Gln Gly Thr Cys
 10 15 20 25
 Gln Gly Ser His Val Ala Gln Ala Cys Val Gly His Cys Glu Ser Ser
 30 35 40
 Ala Phe Pro Ser Arg Tyr Ser Val Leu Val Ala Ser Gly Tyr Arg His
 45 50 55
 Asn Ile Thr Ser Val Ser Gln Cys Cys Thr Ile Ser Gly Leu Lys Lys
 60 65 70
 Val Lys Val Gln Leu Gln Cys Val Gly Ser Arg Arg Glu Glu Leu Glu
 75 80 85
 Ile Phe Thr Ala Arg Ala Cys Gln Cys Asp Met Cys Arg Leu Ser Arg
 90 95 100 105
 Tyr

<210> 3
 <211> 109
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> (2)...(26)
 <223> Xaa is any amino acid

<221> VARIANT
 <222> (27)...(34)
 <223> Xaa is any amino acid or not present

<221> VARIANT
 <222> (40)...(54)
 <223> Xaa is any amino acid

<221> VARIANT
 <222> (55)...(72)
 <223> Xaa is any amino acid or not present

<221> VARIANT
 <222> (74)...(93)
 <223> Xaa is any amino acid

<221> VARIANT
 <222> (94)...(106)
 <223> Xaa is any amino acid or not present

<223> polypeptide motif

<400> 3

```

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1      5      10      15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20      25      30
Xaa Xaa Cys Xaa Gly Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35      40      45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50      55      60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
 65      70      75      80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85      90      95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
 100      105

```

<210> 4

<211> 387

<212> DNA

<213> Artificial Sequence

<220>

<221> sig_peptide

<222> (1)...(69)

<223> degenerate sequence

<221> variation

<222> (1)...(387)

<223> n is any nucleotide

<400> 4

```

atgccnatgg cnwsnccnca racnytngtn ynttayytny tngtnytngc ngtnacngar      60
gcntggggnc argargcngt nathccnggn tgycaaytnc aycnttyaa ygtnacngtn      120
mgnwsngaym gncarggnac ntgycarggn wsncaygtng cncargcntg ygtnggncay      180
tgygarwsnw sngcnttycc nwsnmgntay wsngtnytng tngcnwsngg ntaymgncay      240
aayathacnw sngtnwsnca rtgytgyacn athwsnggny tnaaraargt naargtnicar      300
ytncartgyg tnggnwsnmg nmngngargar ytngaratht tyacngcnmg ngcntgycar      360
tgygayatgt gymgnytnws nmngntay                                     387

```

<210> 5

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 5
cntgygtngg ncaytgy 17

<210> 6

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 6
nntgydnngg nbvntgy 17

<210> 7

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 7
nnacrhnncc nvbnacr 17

<210> 8

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 8

mgngcntgyc artgyga

17

<210> 9

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 9

nnnnvntgyv rntgydv

17

<210> 10

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 10

nnnnbnacrb ynacrhb

17

<210> 11

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 11

tgycartgyg ayatgtg

17

<210> 12

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 12

tgycantgyg anrwrtg

17

<210> 13

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 13

acrgtnacrc tnywyac

17

<210> 14

<211> 17

<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer

<221> variation
<222> (1)...(17)
<223> n is any nucleotide

<400> 14
cntgygtngg ncaytgy

17

<210> 15
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer

<221> variation
<222> (1)...(17)
<223> n is any nucleotide

<400> 15
sntgygwnngg ncaytgy

17

<210> 16
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer

<221> variation
<222> (1)...(17)
<223> n is any nucleotide

<400> 16
snacrcwncc ngtracr

17

<210> 17
<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 17

wsncartgyt gyacnat

17

<210> 18

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 18

wsncantgyt gymsnmy

17

<210> 19

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 19

wsngtnacra crksnkr

17

<210> 20

<211> 17

10

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 20

cayccnttya aygtnac

17

<210> 21

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 21

mrncmnywyw aygtnrm

17

<210> 22

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<221> variation

<222> (1)...(17)

<223> n is any nucleotide

<400> 22

kyngknrwrw trcanyk

17

<210> 23

<211> 48

11

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 23

gtctgggttc gctactcgag gcggccgcta tttttttttt tttttttt

48

<210> 24

<211> 472

<212> DNA

<213> Artificial Sequence

<220>

<223> expressed sequence tag

<400> 24

ccagcaggag	gcacaggaaa	actgcaagcc	gctctgttcc	tgggcctcgg	aagtgatgcc	60
tatggcgtcc	cctcaaacc	tggtcctcta	tctgctggtc	ctggcagtca	ctgaagcctg	120
gggccaggag	gcagtcaccc	caggctgcca	cttgaccccc	ttcaatgtga	cagtgcgaag	180
tgaccgcaa	ggncacctgc	cagggtccc	acgtggcaca	ggcctgtgtg	ggccactgtg	240
agtccagcgc	cttccttct	cggtactctg	tgctgggtggc	cagtgggttac	cgacacaaca	300
tcacctccgt	ctctcagtgc	tgcaccatca	gtggcctgaa	gaagtcaaag	tacagctgca	360
gtgtgtgggg	agccggaggg	aggagtcgag	atcttcaggc	cagggtgcc	atgtgacatg	420
tgctgcctct	ctcgctacta	gccatcctc	tcccctcctt	cctcccctgg	gg	472

<210> 25

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 25

ccagcacaga gtaccgagaa gg

22

<210> 26

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

12

<400> 26
 tggtcctggc agtcactgaa gc 22
 <210> 27
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> oligonucleotide primer

<400> 27
 ggccctgccag tgtgacat 18
 <210> 28
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> oligonucleotide primer

<400> 28
 cccccaccag aatgtcaa 18
 <210> 29
 <211> 129
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> SIGNAL
 <222> (1)...(23)
 <223> engineered variant

<400> 29
 Met Pro Met Ala Ser Pro Gln Thr Leu Val Leu Tyr Leu Leu Val Leu
 -20 -15 -10
 Ala Val Thr Glu Ala Trp Gly Gln Glu Ala Val Ile Pro Gly Cys His
 -5 1 5
 Leu His Pro Phe Asn Val Thr Val Arg Ser Asp Arg Gln Gly Thr Cys
 10 15 20 25

[illegible]

<210> 30
<211> 387
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence

```
<221> variation
<222> (1)...(387)
<223> n is any nucleotide
```

<400>	30						
atgccnatgg	cnwsnccnca	racnytngt	ytntayytny	tngtnytngc	ngtnacngar		60
gcntggggnc	argargcngt	nathccnggn	tgycayytn	ayccnttyaa	ygtnacngtn		120
mgwnsngaym	gncarggnac	ntgycarggn	wsncaygtng	cncargcntg	ygtnngncay		180
tgylarwsnw	sngcnttycc	nwsnmgtay	wsngtnytn	tngcnwsngg	ntaymgncay		240
aayathacnw	sngtnwsnca	rtgytgyacn	athwsnggny	tnaaraargt	naargtncar		300
ytncartgyg	tnggnwsnm	nmngngargar	ytngaratht	tyacngcnmg	nwsntgycar		360
tgylayatgt	gymgnytnws	nmgtay					387

<210> 31
<211> 589
<212> DNA
<213> Mus musculus

```
<220> .  
<221> CDS  
<222> (36)...(422)
```

<400> 31

14

ggagtccttca gttgctgttg gactgtcctt tgcag atg ccc atg gca cca cga	53
Met Pro Met Ala Pro Arg	
1 5	
gtc ttg ctc ctt tgc ctg ctg ggc ctg gca gtc act gaa ggg cat agc	101
Val Leu Leu Cys Leu Leu Gly Leu Ala Val Thr Glu Gly His Ser	
10 15 20	
cca gag aca gcc atc cca ggc tgc cac ttg cac ccc ttc aat gtg acg	149
Pro Glu Thr Ala Ile Pro Gly Cys His Leu His Pro Phe Asn Val Thr	
25 30 35	
gtg cgc agt gat cgc ctc ggc act tgc cag ggc tcc cac gtg gca cag	197
Val Arg Ser Asp Arg Leu Gly Thr Cys Gln Gly Ser His Val Ala Gln	
40 45 50	
gcc tgt gta gga cac tgt gag tct agt gct ttc cct tcc cgg tac tct	245
Ala Cys Val Gly His Cys Glu Ser Ser Ala Phe Pro Ser Arg Tyr Ser	
55 60 65 70	
gtg ctg gtg gcc agt ggc tat cgg cac aac atc acc tct tcc tcc cag	293
Val Leu Val Ala Ser Gly Tyr Arg His Asn Ile Thr Ser Ser Ser Gln	
75 80 85	
tgc tgc acc atc agc agc ctc aga aag gtg agg gtg tgg ctg cag tgc	341
Cys Cys Thr Ile Ser Ser Leu Arg Lys Val Arg Val Trp Leu Gln Cys	
90 95 100	
gtg ggg aac cag cgt ggg gag ctt gag atc ttt act gca agg gcc tgc	389
Val Gly Asn Gln Arg Gly Glu Leu Glu Ile Phe Thr Ala Arg Ala Cys	
105 110 115	
cag tgt gat atg tgc cgt ttc tcc cgc tac tag tccccgaagg gctcaggctc	442
Gln Cys Asp Met Cys Arg Phe Ser Arg Tyr *	
120 125	
cggtcctgcc actgacatgt catgggtatc tcaaactcgg ggctctgacc ctctttatcg	502
tctgtgaaga tgaggttggc cctctcagca gtctccttgc tacattcttc ctctgctcct	562
gtcctcaata aagcaagcaa tgcttga	589

<210> 32
<211> 128
<212> PRT
<213> Mus musculus

15

<400> 32

```

Met Pro Met Ala Pro Arg Val Leu Leu Leu Cys Leu Leu Gly Leu Ala
 1           5           10           15
Val Thr Glu Gly His Ser Pro Glu Thr Ala Ile Pro Gly Cys His Leu
      20           25           30
His Pro Phe Asn Val Thr Val Arg Ser Asp Arg Leu Gly Thr Cys Gln
      35           40           45
Gly Ser His Val Ala Gln Ala Cys Val Gly His Cys Glu Ser Ser Ala
      50           55           60
Phe Pro Ser Arg Tyr Ser Val Leu Val Ala Ser Gly Tyr Arg His Asn
65           70           75           80
Ile Thr Ser Ser Ser Gln Cys Cys Thr Ile Ser Ser Leu Arg Lys Val
      85           90           95
Arg Val Trp Leu Gln Cys Val Gly Asn Gln Arg Gly Glu Leu Glu Ile
      100          105          110
Phe Thr Ala Arg Ala Cys Gln Cys Asp Met Cys Arg Phe Ser Arg Tyr
      115          120          125

```

<210> 33

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 33

gtcggtgctc agcattcact actcgagggt tttttttttt ttttttt

47

<210> 34

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 34

cctgggcctc ggaagtga

18

<210> 35

<211> 18

<212> DNA

<213> Artificial Sequence

16

<220>

<223> oligonucleotide primer

<400> 35

aaactcccct cttctcag

18

<210> 36

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 36

cgtaatacga ctcactatag ggcgaattgg

30

<210> 37

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer

<400> 37

gaaacagcta tgaccatgat tacgcca

27

<210> 38

<211> 767

<212> DNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (203)...(595)

<400> 38

gcaggaggca cctggagtct acagttcctg ccggactgag tagctgaggc aaggaagcaa	60
gcaccccaca cattcccacc caaggcagag aggatcaaca gtgccacca ggcacacctc	120
acagtcggaa gacccagaag cctggcttgc tgggggagag acacaactgc aaagacttcc	180

17

cttccacccc actccttttc ag atg ccc atg gca cct cga gtc ttg ctc ttc 232
Met Pro Met Ala Pro Arg Val Leu Leu Phe
1 5 10

tgc ctg ctg ggt ctg gca gtc act gaa ggg cat ggc ctg gag gca gcc 280
Cys Leu Leu Gly Leu Ala Val Thr Glu Gly His Gly Leu Glu Ala Ala
15 20 25

gtc cca atc cca ggc tgc cac ttg cac ccc ttt aac gtg aca gtg cga 328
Val Pro Ile Pro Gly Cys His Leu His Pro Phe Asn Val Thr Val Arg
30 35 40

agt gat cgc cat ggc acc tgc cag ggc tcc cat gtg gca cag gcg tgt 376
Ser Asp Arg His Gly Thr Cys Gln Gly Ser His Val Ala Gln Ala Cys
45 50 55

gta gga cac tgt gag tct agt gct ttc cct tct cgg tac tct gtg ctg 424
Val Gly His Cys Glu Ser Ser Ala Phe Pro Ser Arg Tyr Ser Val Leu
60 65 70

gtt gcc agt ggc tat cga cac aac atc acc tct gtc tct cag tgc tgt 472
Val Ala Ser Gly Tyr Arg His Asn Ile Thr Ser Val Ser Gln Cys Cys
75 80 85 90

acc atc agc agc ctt aaa aag gtg agg gtg tgg ctg cac tgc gtg ggg 520
Thr Ile Ser Ser Leu Lys Lys Val Arg Val Trp Leu His Cys Val Gly
95 100 105

aac cag cgt ggg gag ctc gag atc ttc acg gct agg gcc tgc cag tgt 568
Asn Gln Arg Gly Glu Leu Glu Ile Phe Thr Ala Arg Ala Cys Gln Cys
110 115 120

gat atg tgc cgt ctc tcc cgc tac tag gccccgaagg gctcaggcct 615
Asp Met Cys Arg Leu Ser Arg Tyr *
125 130

ccagtcctgc cactgatagg tcgtgcttct ctgagaccag ccctcttttg agtctgaaga 675
tggggcttcg cctctgttta cctggcctcc tcagcagtct cactgctgct ttctccttca 735
ccctgtcct caataaagca ggcagtgcct ga 767

<210> 39

<211> 130

<212> PRT

<213> Rattus norvegicus

18

<400> 39

Met Pro Met Ala Pro Arg Val Leu Leu Phe Cys Leu Leu Gly Leu Ala
 1 5 10 15
 Val Thr Glu Gly His Gly Leu Glu Ala Ala Val Pro Ile Pro Gly Cys
 20 25 30
 His Leu His Pro Phe Asn Val Thr Val Arg Ser Asp Arg His Gly Thr
 35 40 45
 Cys Gln Gly Ser His Val Ala Gln Ala Cys Val Gly His Cys Glu Ser
 50 55 60
 Ser Ala Phe Pro Ser Arg Tyr Ser Val Leu Val Ala Ser Gly Tyr Arg
 65 70 75 80
 His Asn Ile Thr Ser Val Ser Gln Cys Cys Thr Ile Ser Ser Leu Lys
 85 90 95
 Lys Val Arg Val Trp Leu His Cys Val Gly Asn Gln Arg Gly Glu Leu
 100 105 110
 Glu Ile Phe Thr Ala Arg Ala Cys Gln Cys Asp Met Cys Arg Leu Ser
 115 120 125
 Arg Tyr
 130

<210> 40

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 40

ccgtttctcc cgctacta

18

<210> 41

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 41

gggccaacct catcttca

18

<210> 42

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC17438)

<400> 42

gatcagggcc ggccaccatg cctatggcgt cc

32

<210> 43

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC17439)

<400> 43

gatcagggcg cgccctagta gcgagagagg cg

32

<210> 44

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC17950)

<400> 44

cgatcgggcc ggccaccatg cccatggcac ca

32

<210> 45

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC17951)

<400> 45

cgtacgggcg cgccctagta gcgggagaaa cg

32

<210> 46

<211> 6

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Peptide tag

<400> 46

Glu Tyr Met Pro Met Glu

1

5

<210> 47

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide

<400> 47

Glu Tyr Met Pro Val Asp

1

5

<210> 48

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC12700)

<400> 48

ggaggtctat ataagcagag c

21

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer (ZC12742)

<400> 49

ttatgtttca gggtcagggg

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/03104

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/475 C12N5/10 C12N15/62 C07K16/26
A61K38/18 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARRA. M., ET AL.: "the WashU-HHMI Mouse EST Project" EMBL SEQUENCE DATA LIBRARY, 5 January 1998, XP002104601 heidelberg, germany accession no. AA709641 ---	1, 3, 4, 6, 7, 15-19
X	WANG, Y., ET AL.: "sequence of a 11q13 bac mapping distal to PYGM and proximal to D11S4936" EMBL SEQUENCE DATA LIBRARY, 19 March 1997, XP002104602 heidelberg, germany accession no. AC000159 --- -/--	15, 19

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 June 1999

Date of mailing of the international search report

15/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/03104

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SUN, P.D. AND DAVIES, D.R.: "the cysteine-knot growth factor superfamily" ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 24, 1995, pages 269-291, XP002104603 see the whole document	1-28
A	MEITINGER, T., ET AL.: "molecular modelling of the norrie disease protein predicts a cysteine knot growth factor tertiary structure" NATURE GENETICS, vol. 5, December 1993, pages 376-380, XP002104604 see abstract; figure 1	1-28
A	MCDONALD N G ET AL: "A STRUCTURAL SUPERFAMILY OF GROWTH FACTORS CONTAINING A CYSTINE KNOT MOTIF" CELL, vol. 73, 7 May 1993, pages 421-424, XP002913231 see the whole document	1-28